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1. Las Trombospondinas 
 
 
Las trombospondinas (TSPs) son glicoproteínas que se secretan a la 
matriz extracelular.  Poseen una estructura de multidominios con sitios de unión 
a calcio (Ca2+).  Desde un punto de vista evolutivo, pertenecen a una familia de 
proteínas ancestrales, que están presentes tanto en protóstomos (e.g. 
Drosophila melanogaster, Anopheles gambiae) como en deuteróstomos (e.g. 
vertebrados).  Cinco de sus miembros están codificadas en el genoma humano 
(TSP1 a TSP5) y cuatro de estas cinco TSPs han sido identificadas en otros 
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Se puede hablar de dos subclases principales de TSPs, -A y -B 
atendiendo a su ensamblaje en forma de trímeros o pentámeros, 
respectivamente (2).  La subclase-A (TSP1 y TSP2) forma trímeros de 
subunidades compuestas por: dominio N-terminal, un dominio de 
oligomerización, un dominio con el factor de von Willebrand de tipo C (VWC), 
tres dominios de repetición de tipo 1 (TSRs) o motivos de tipo properdina, un 
dominio de identidad que contiene tres motivos de homología al factor de 
crecimiento epidérmico (EGF), un haz de unión de Ca2+ y un dominio C-terminal 
de tipo lectina (Figura 1) (3).  La subclase-B (TSP3-5 y TSPs de artrópodos) 
forma pentámeros, carece del dominio VWC y de los dominios TSRs, aunque 
tiene motivos adicionales de tipo EGF (Figura 1) (3).  A pesar de estas 
diferencias, todas las TSPs comparten un dominio de identidad C-terminal muy 













Figura 1.  Estructura modular de los miembros de la familia de Trombospondinas 
(Adaptado de Carlson, C.B., et al., 2008)
Código de colores: dominio N-terminal (rojo), dominio de oligomerización (naranja), 
dominio con factor de von Willebrand de tipo C (VWC) (amarillo), tres dominios de 
repetición de tipo 1 (TSRs) o motivos de tipo properdina (verde), tres motivos de 
homología al factor de crecimiento epidérmico (EGF) (verde-azulado, con sitios 
conocidos o no de unión al calcio mas oscuros), un haz de unión de calcio (azul) y un 
dominio globular C-terminal de tipo lectina (morado) (Carlson, C.B., et al., 2008). 
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Las TSPs se expresan en vertebrados durante el desarrollo embrionario 
y en tejidos de adulto con un patrón de expresión espacio-temporal específico 






(*): b=bovino, p=pollo, h=humano, r=ratón, c=cerdo, x=Xenopus 
Tabla 1.  Pricipales sitios de expresión de las Trombospondinas 
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En el adulto la mayor parte de los tejidos expresan al menos un tipo de 
TSP, no obstante, los distintos miembros de esta familia a menudo se expresan 
en poblaciones celulares diferentes dentro de un mismo tejido.  Así TSP1 
procede mayoritariamente de los gránulos-α de las plaquetas; aunque también 
se acumula en lesiones ateroscleróticas, y en tejido sinovial reumático.  Además 
la TSP1 junto con la TSP2 se expresan de forma abundante en fibroblastos del 
estroma de tumores y en células endoteliales durante la progresión tumoral (4), 
quizás como mecanismo de defensa del propio organismo contra el tumor (5).  
También se expresan en procesos de renovación de tejidos como son la 
cicatrización de heridas en piel, músculo, y sistema nervioso central procedente 
de macrófagos o células de microglia, fibroblastos, y células endoteliales.  Esto 
explicaría que los ratones con doble deficiencia en TSP1/TSP2 poseen una 
cicatrización anómala y persistencia del proceso inflamatorio (6).  La TSP3 se 
expresa abundantemente en osteosarcoma metastásico (7).  La TSP4 se 
expresa de forma diferente en carcinoma lobular invasivo/cáncer invasivo ductal 
(8).  Se ha demostrado que los TSRs de TSP1 y TSP2, tienen cierto impacto en 
su actividad anti-angiogénica, por lo tanto, no cabría esperar que TSP3, 4 y 5, 
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La transcripción de la TSP4 está también regulada de forma positiva en 
el músculo esquelético de pacientes con distrofia muscular de Duchenne y con 
deficiencia en α-sarcoglicano (9).  La TSP5 o COMP (cartilage oligomeric matrix 
protein) y fragmentos de la misma están presentes en cartílago dañado, suero y 
fluído procedente de líquido sinovial asociado con osteoartritis, lesiones en 
articulaciones y en procesos degenerativos del cartílago (10, 11).  
 
Aunque hay muchos trabajos que describen las propiedades de los 
miembros de esta familia de TSPs, los estudios han centrado más su atención 
en la TSP1 y TSP2, existiendo estudios detallados sobre su síntesis y 
degradación.  La expresión de la TSP1 está regulada a nivel transcripcional a 
través de múltiples sitios de unión en la región 5’ del gen de la TSP1 en 
respuesta a numerosos estímulos extracelulares (12-14).  El control post-
transcripcional de la estabilidad del mRNA también está implicado en la 
regulación del gen (14, 15).  Además, se han descrito mecanismos epigenéticos 
como la hipermetilación de islas CpG en torno al sitio de inicio de transcripción 
que están implicados en el silenciamiento de la TSP1 en algunos tipos de 





                                                                                                      Thrombospondin-1 
 
 
Otro de los factores epigenéticos que regula directa e indirectamente la 
expresión de TSP1 es la hipoxia (18-21). 
 
Las TSPs pueden permanecer retenidas en la matriz extracelular (ECM), 
aunque también pueden ser degradadas tanto en el exterior como en el interior 
celular.  Por ejemplo, durante los procesos de fibrinólisis y resolución de 
coágulos la TSP1 es sustrato de degradación por la trombina y el Factor XVIIIa.  
TSP1 también es sustrato de catepsinas y elastasas producidas por leucocitos y 
neutrófilos durante la respuesta inflamatoria (22).  La TSP5 es sustrato de 
metaloproteinasas (MMPs) como la MMP19 y MMP20 y también de otras 
proteasas como las ADAMTS (membrane proteins containing a disintegrin and a 
metalloproteinase with TSPs motifs) (23, 24).  La TSP1 y TSP2 también están 
sujetas a endocitosis y posterior degradación lisosomal en el interior celular.  El 
proceso de endocitosis es rápido y está mediado por interacciones del dominio 
N-terminal de la TSP con proteoglicanos tipo heparán sulfato (HSPG) y 
proteínas relacionados con el receptor de lipoproteínas de baja densidad (LRP), 
formando un complejo con la calreticulina (25).  Las TSPs también pueden 
permanecer retenidas en la matriz extracelular, y en el caso de la TSP1 el 
mecanismo de retención requiere del dominio C-terminal en su forma trimérica, 
del motivo RGD, y de un nuevo motivo en el dominio L-lectina (26). 
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1.1. La Trombospondina-1 
 
 
La TSP1 se describió en 1971 por Baenziger et al. (27), siendo el primer 
miembro de esta familia descrito y además el más estudiado.  El nombre de 
esta glicoproteína viene de  “Thrombin Stimulated Platelets“, ya que fue 
identificada como una proteína liberada por los gránulos-α de las plaquetas en 






La compleja naturaleza de las TSPs hace imposible resolver la 
estructura de la molécula completa por resonancia magnética nuclear (NMR) y 
por cristalografía de rayos-X.  El problema se ha solucionado estudiando sus 
fragmentos recombinantes.  Estas estructuras proporcionan un modelo de 













1.1.1. A. Dominio N-terminal  
Figura 2.  Modelo de la estructura completa de la Trombospondina-1 y la 
Trombospondina-2 
(Adaptado de Carlson, C.B., et al., 2008) 
Código de colores: dominio N-terminal (rojo), dominio de oligomerización (naranja), 
dominio con factor de von Willebrand de tipo C (VWC) (amarillo), tres dominios de 
repetición de tipo 1 (TSRs) o motivos de tipo properdina (verde), tres motivos de 
homología al factor de crecimiento epidérmico (EGF) (verde-azulado, con sitios 
conocidos o no de unión al calcio mas oscuros), un haz de unión de calcio (azul) y un 
dominio globular C-terminal de tipo lectina (morado), iones de calcio (esferas rojas), 
azucares del dominio de identidad (palitos Corey-Pauling-Kultin (CPK) verdes), sitios 
posibles de flexibilidad estructural (negro), sitios de modificaciones co-traduccionales 
(rojo) y modificaciones post-traduccionales (azul) (Carlson, C.B., et al., 2008). 
 
 
Mediante búsquedas realizadas usando algoritmos basados en la 
homología de estructura, se ha emplazado el dominio N-terminal de TSP1 en la 
superfamilia de lectinas de tipo concanavalina A/glucanasas (29).   
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La estructura globular en β-sandwich tiene 13 hebras-β antiparalelas y 6 
hélices-α, siendo la hélice α3 la más larga y cruza por encima de las dos 
láminas-β.  Además existe una hélice-α adicional localizada cerca del extremo 
C-terminal del dominio.  El residuo Cys214 contenido en esta hélice, forma un 
puente disulfuro con el residuo Cys153 ubicado en el bucle β11-β12.  Este 
puente disulfuro aproxima el extremo C-terminal al resto del dominio N-terminal 




Figura 3.  Estructura del dominio N-terminal de la Trombospondina-1 cristalizado  
(Carlson, C.B., et al., 2008)
La estructura y los sitios de unión 
están coloreados de la siguiente 
manera: sitio de unión de heparina 
(palitos CPK azules), sitios de unión de 
fibrinógeno y α4β1 (verde), sitio de 
unión de calreticulina (naranja), bucle 
β13- β14 cubriendo la hendidura 
donde potencialmente se unen 
hidratos de carbono (amarillo), puente 
disulfuro (palitos CPK) (Carlson, C.B., 
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1.1.1. B. Dominio trimérico de oligomerización  
Aunque la estructura del dominio de oligomerización en forma trimérica 
no se ha resuelto, sin embargo la estructura del dominio de oligomerización 
trimérico de matrilina-1 (chicken cartilage matrix protein), proporciona 
información acerca de la estructura de este dominio de TSP1 y TSP2 (30).  El 
interior de este dominio es hidrofóbico y puede ser rígido.  La superficie del 
dominio es hidrofílica y relativamente desordenada.  El punto de unión entre el 
módulo N-terminal y el dominio de oligomerización (25 residuos), y el punto de 
unión entre el dominio de oligomerización y el módulo VWC (11-17 residuos) 
son sitios flexibles y sensibles a la actividad de proteasas (31).   
 
 
1.1.1. C. Dominio con el factor de von Willebrand de tipo C 
 
 
TSP1 y TSP2 contienen un único módulo vWC, conocido también como 
repetición de tipo cordina rica en cisteinas (chordin-like cysteine-rich repeat) o 
módulo N-terminal de pro-colágeno fibrilar (N-terminal fibrillar pro-collagen 
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La estructura atómica de este módulo no se ha resuelto, aunque se tiene 
información del módulo vWC de TSP1 gracias a estudios biofísicos de baja 
resolución (32).  Este dominio contiene 10 residuos de cisteina, con un grado de 
conservación relativamente bajo, a excepción de las cisteinas segunda y octava 
(33).  Su análisis mediante espectrometría de masas revela que se trata de un 
modulo glicosilado en el que todos los residuos de cisteina están implicados en 
la formación de puentes disulfuro que estabilizan la proteína. 
 
 
1.1.1. D. Dominios de repetición o TSRs. 
 
 
TSP1 y TSP2 contienen tres TSRs en tándem.  Estos TSRs, de unos 60 
amino ácidos de longitud, están evolutivamente conservados y contienen unos 
12 residuos invariables que consisten en 6 cisteinas, 2 residuos de arginina y 2 
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En estos dominios se han descrito dos tipos de glicosilación poco 
comunes: La C-manosilación de los residuos de triptófano, co-traduccional y 
mediada por la enzima dolichol-P-manosa.  Esta tiene lugar en la secuencia 
WXXW del TSR (36); y la O-fucosilación, modificación post-traduccional 
mediada por la enzima O-fucosiltransferasa-2, que tiene lugar en la secuencia 
CSX(S/T)C del TSR en residuos de serina o treonina (37) y que es crítica en el 
proceso de maduración y secreción de la proteína (37, 38).   
 
 
1.1.1. E. Dominio de identidad 
 
 
Esta porción de la proteína incluye los motivos en tándem de tipo EGF, 
13 sitios de unión al Ca2+ que constituyen el haz de unión de Ca2+ y un módulo 
C-terminal de tipo lectina.  En la familia de las TSPs la diferencia más grande en 
estos dominios de identidad se encuentra en el número de motivos de tipo EGF 
(3 en la TSP1 y TSP2) (1).  EGF1 contiene un sitio que está modificado por la 
enzima glucosa-xilosa disacaridasa en TSP1 bovina.  EGF2 une un único Ca2+ 
en la interfase entre EGF1 y EGF2 y probablemente estabiliza las interacciones 
entre los módulos.   
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EGF3 interacciona con EGF2, con las porciones N- y C-terminal del haz 
de unión de Ca2+ y con el módulo de tipo lectina.  El haz de unión de Ca2+ forma 
una estructura estable, dependiente de Ca2+ e independiente del resto del 
dominio de identidad y transmite los cambios alostéricos inducidos por iones de 
Ca2+ a otras partes de TSP (3, 39).  Este dominio consta de 13 motivos ricos en 
aspartato que forman conformaciones globulares individuales conectadas y 
estabilizadas por puentes disulfuro.  Como media, cada motivo une dos iones 
Ca2+, y la unión de los mismos causa un cambio conformacional en la proteína 
que ayuda a mantener los dominios de identidad de la TSP en una 
conformación más compacta (40).  En cuanto a su estructura, el módulo de tipo 
lectina está compuesto por una hélice-α y dos láminas-β, cada una de las 
cuales continen siete hebras-β.  De las dos láminas-β, una forma una curva 
convexa en la superficie de la proteína y la otra está más doblada hacia el 
interior de la proteína.  La hélice-α se sitúa en la hendidura formada por la 
segunda lámina-β.  La búsqueda de homologías usando algoritmos basados en 
estructura, sitúan este módulo dentro de la familia con dominios de lectina de 
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1.1.2.Principales sitios de expresión 
 
 
La TSP1 se expresa en diversos tejidos en el adulto y también durante el 
desarrollo, siempre con un patrón de expresión complejo.  No obstante, los 
principales cambios ocurren durante condiciones fisiopatológicas.  Por ejemplo, 
en respuesta a daños tisulares se liberan de forma rápida y transitoria  
concentraciones elevadas de TSP1 (6, 41).  La TSP1 se expresa durante la 
cicatrización de lesiones en la piel, el hueso (42), el músculo, el nervio (43, 44), 
en lesiones ateroscleróticas e hiperplasia de la íntima (45, 46).  La TSP1 se 
expresa durante la coagulación con una distribución espacio-temporal 
característica (47).  Además la TSP1 está elevada en algunas enfermedades 
coronarias crónicas (48).  Se expresa también en los fibroblastos de la córnea e 
iris en el síndrome de pseudoexfoliación (49), en el sinovium reumático (50) y 
en los fibroblastos del estroma de tumores y células endoteliales durante 
estadíos tempranos de la progresión tumoral (4), quizás como un mecanismo de 
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No obstante, con frecuencia la expresión de la TSP1 se pierde durante la 
progresión del tumor.  Esto se debe en parte a la regulación negativa mediada 
por oncogenes tales como Ras, Myc, y otros factores como Id1, y también en 
parte a la ausencia de regulación positiva por parte de genes supresores de 






La TSP1 se une a glicoproteínas transmembrana que sirven de 
receptores de señalización.  Así se ha visto que se une a integrinas activadas 
de tipo α3β1, α6β1, α9β1, y α4β1 (3, 55-57).  Los sitios de unión para estos 
receptores han sido mapeados usando péptidos sintéticos.  El dominio N-
terminal de TSP1 contiene sitios consenso BBXB de alta afinidad de unión a 
heparina/HSPG.  Los TSRs contribuyen a la unión de heparina con múltiples 
sitios de baja afinidad (58, 59), estos también median interacciones de TSP1 
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Además la TSP1 también se une a otras moléculas extracelulares tales 
como componentes de matriz, proteasas, citoquinas y factores de crecimiento.  
Entre estos encontramos la decorina (64), fibrinógeno (29), calreticulina (3),  
LRP (65), fibronectina (66), la metaloproteinas de tipo 2 (MMP-2) (67), y TGF-β1 
(68).  El motivo WSHWSPW en el segundo TSR se une a TGF-β1 latente.  
Como resultado, TGF-β1 maduro y activo se libera por efecto de la interacción 
molecular con el motivo KRFK en el primer TSR de la TSP1 (68).  Esta 
interacción con TGF-β1 es relevante para la función homeostática de TSP1.  El 
haz de unión de Ca2+ en TSP1 contiene también sitios de unión para integrinas 
de tipo αvβ3 y αIIbβ3 (69), y otras proteínas como la catepsina G y la elastasa 
de neutrófilos (70).  El módulo C-terminal de TSP1 de tipo lectina contiene el 
sitio de unión para CD47 (71).   
 
A menudo, la unión de la TSP1 a otras moléculas modula la actividad de 
las mismas.  Por ejemplo, la unión de TSP1 a catepsina G y elastasa de 
neutrófilos o MMP-2 disminuye la actividad catalítica de estas enzimas.  Este 
proceso puede ser importante para la fibrilogénesis del colágeno y para la 
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La expresión diferencial y el grado de activación de los receptores 
celulares en membrana para la TSP1, tales como integrinas, CD36, CD47, LRP, 
proteoglicanos y sulfátidas, puede determinar que haya respuestas específicas 
a TSP1 dependientes de cada tipo celular (72-74). 
 
 
1.1.4.Funciones de la Trombospondina-1 
 
 
Tanto el estudio de ratones deficientes para el gen de la TSP1 (75), 
como la existencia de enfermedades genéticas humanas relaccionadas con la 
ausencia de la TSP1 ponen en evidencia funciones específicas de la proteína in 
vivo.   
 
Los ratones genéticamente nulos para la TSP1 son fértiles y se 
desarrollan con normalidad.  No obstante, la viabilidad del embrión está 
disminuida, y los fenotipos incluyen pneumonía (a partir de un mes de edad), 
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La pneumonía e inflamación anormal en los pulmones y el páncreas 
propia de los ratones nulos para la TSP1, presenta muchas similitudes 
fenotípicas con los ratones nulos para TGF-β1 (76) y son una consecuencia de 
la falta específica de activación de TGF-β1 en estos tejidos.  Aunque la TSP1 
no es el único activador de TGF-β1, parece tener un papel dominante en la 
activación del mismo en estos dos tejidos, requisito necesario tanto para una 
homeostasis epitelial normal como para el control de las respuestas inmunes 
(77).  Además de estos defectos menores, se han descrito funciones 
adicionales de la TSP1 al al someter a estos ratones a determinados tipos de 
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Los estudios funcionales han puesto de manifiesto que la TSP1 participa 
además en procesos celulares tales como, adhesión, organización del 
citoesqueleto, migración, crecimiento de neuritas, agregación celular, 





Figura 4.  Diagrama esquemático de las interacciones moleculares y las funciones de 





                                                                                                      Thrombospondin-1 
 
 
La TSP1 sirve de sustrato para la adhesión de muchos tipos celulares.  
Después de la adhesión, las células pueden permanecer redondas y estáticas o 
extenderse y hacerse móviles.  Los fenómenos de extensión celular y migración 
sobre sustratos de TSP1 se asocian con procesos de organización del 
citoesqueleto cortical que conllevan la formación de largos lamelipodios (79).  
Los efectos de la TSP1 en el citoesqueleto de actina son diversos y dependen 
del tipo celular.  Las células mesangiales intraglomerulares, monocitos, 
neutrófilos, células de músculo liso, mioblastos esqueléticos y células de 
carcinoma, son algunos ejemplos de células que se extienden y adquieren 
movilidad en presencia de TSP1.  Los efectos de la TSP1 en la movilidad de 
células vasculares de músculo liso (VSMC) son relevantes en el contexto de 
lesiones ateroscleróticas y vasculares.  Los fenómenos de quimiotaxis en 
respuesta a TSP1 dependen de los receptores CD47, integrinas de tipo αv (80), 
e integrinas de tipo β1 (81).  El tratamiento de arterias dañadas con anticuerpos 
contra el sitio de unión a CD47 en TSP1 reduce el engrosamiento de la 
neoíntima (82).  Además, se han descrito polimorfismos en TSP1, TSP2 y TSP4 
que aumentan el riesgo de sufrir enfermedad coronaria prematura, 
probablemente debido a un incremento de la actividad pro-aterogénica o pro-
trombótica (83).  No obstante, un análisis reciente de poblaciones más grandes 
ha puesto en duda la validez de esta asociación (84). 
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Por otro lado, la TSP1 es un fuerte antagonista de la relajación de VSMC 
promovida por óxido nítrico (NO), sugiriendo que la TSP1 juega un papel 
importante en el control de la perfusión de los tejidos (85).  Tras un accidente 
isquémico agudo, ratones nulos para TSP1 y CD47 presentan un mayor índice 
de supervivencia del tejido (86, 87).  Además la TSP1 también promueve 
fenómenos de adhesión y agregación célula-célula.  Así, participa en la 
adhesión de eritrocitos (RBCs) infectados con el parásito de la malaria al 
endotelio vascular (88).  La TSP1 se une directamente a los eritrocitos en forma 
de hoz (Sickle RBCs) (89) y participa en su adhesión a células endoteliales in 
vitro (90), contribuyendo a la patogénesis de oclusión vascular característica de 
la enfermedad de Sickle. 
 
La TSP1 también juega un papel importante en la fisiología plaquetaria 
(agregación plaquetaria y formación del coágulo de fibrina).  Así regula la 
fisiología plaquetaria mediante la prevención de la degradación del factor de von 
Willebrand por la proteasa plamática ADAMTS-13.  Esto se pone de manifiesto 
en ratones nulos para TSP1 que presentan una adhesión defectuosa de los 
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Un segundo mecanismo a través del cual la TSP1 modula la fisiología 
plaquetaria consite en la inhibición de la actividad fisiológica anti-trombótica del 
NO (92).  El NO juega un papel fundamental en la fisiología plaquetaria, al 
limitar su agregación (93).  Tanto la proteína completa como fragmentos 
recombinantes de los TSRs y del dominio C-terminal, inhiben el retraso en la 
agregación promovido por el NO mediante un mecanismo que implica la 
inhibición de múltiples pasos en la cascada de señalización del NO/cGMP (92).   
 
Los efectos de la TSP1 en la proliferación celular son también 
específicos del tipo celular.  Por ejemplo, la TSP1 coopera con factores de 
crecimiento tales como EGF o PDGF para promover la proliferación de SMC 
(94).  En el caso de células endoteliales, TSP1 inhibe la proliferación e induce 
activamente la apoptosis (95-97).  CD36 se considera un receptor crítico en la 
actividad anti-angiogénica de la TSP1, dado que en un modelo experimental de 
angiogénesis en la córnea de ratones nulos para CD36 no se observa actividad 
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No obstante, la cornea avascular es un tejido especializado que se 
mantiene gracias a la sobre-expresión del receptor-1 del factor de crecimiento 
de endotelio vascular (VEGF) en forma soluble (99).  Este ambiente es 
permisivo para la angiogénesis estimulada por el factor de crecimiento de 
fibroblastos (FGF)-2 que es independiente del NO, pero no para la angiogénesis 
estimulada por VEGF que está mediada por NO.  Al contrario que en el modelo 
experimental de angiogénesis en la córnea, el crecimiento de vasos en 
explantes musculares procedentes de ratones nulos para CD36 permanece 
sensible a la inhibición por TSP1 (87).  Esto indica que existen otros receptores 
de la TSP1 que estarían mediando esta actividad (100).  Los motivos peptídicos 
adyacentes al sitio de unión de CD36 también inhiben angiogénesis.  Estos 
motivos peptídicos podrían fortalecer la unión de TSP1 a CD36 o tener efectos 
indirectos tales como el secuestro de factores pro-angiogénicos (97, 101, 102).  
Aunque la interacción de TSP1 con CD36 juega un papel importante en la 
actividad anti-angiogénica de la TSP1, también se han identificado mecanismos 
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Los TSRs pueden unir integrinas de tipo β1 (62) y estimular la migración 
de células endoteliales (103).  CD47 también se ha relacionado con un 
incremento en la apoptosis de células endoteliales (104).  Y por último, péptidos 
del dominio de identidad de TSP1 de unión a CD47 también inhiben 
angiogénesis en la córnea de ratón (105).  El crecimiento de vasos en explantes 
de músculo procedentes de ratones nulos para CD47 no es susceptible de 
inhibición por TSP1, indicando que CD47 es necesario para la respuesta anti-
angiogénica de TSP1 en este ensayo (106).  Además, TSP1 y dominios 
recombinantes de esta no inhiben la vía de señalización del NO en células 
endoteliales procedentes de ratones nulos para TSP1.  Para terminar, la 
angiogénesis en injertos de piel de espesor total está potenciada en ratones 
nulos para TSP1 y CD47 pero no en los ratones nulos para CD36 (107).  Por lo 
tanto CD47 y no CD36, es el receptor de TSP1 esencial para la inhibición de 
angiogénesis en isquemia.   
 
Además, TSP1 inhibe angiogénesis a través de sus efectos en la 
biodisponibilidad de VEGF.  La TSP1 bloquea la liberación de VEGF desde 
ECM inhibiendo la activación de MMP-9 (108).  Esta también se une 
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La TSP1 activa TGF-β latente en el entorno del tumor (110) y esta 
actividad también podría contribuir al letargo del tumor.  A menudo, TSP1 está 
regulada negativamente durante la progresión tumoral (111) y esta pérdida se 
asocia a alteraciones en oncogenes específicos y genes supresores de tumores 
(p53, Myc, Ras) que controlan la expresión de TSP1 (51, 53).   
  
 
1.1.4.A. Regulación de las Respuestas Inmunes 
 
Los ratones nulos para TSP1 manifiestan un fenotipo que incluye 
infiltrados inflamatorios pulmonares agudos y crónicos, y un número elevado de 
leucocitos en circulación (77), lo cual sugiriere que la TSP1 tiene también un 
papel anti-inflamatorio.  Como se menciona previamente en la página 19, la 
pneumonía e inflamación anormal en los pulmones y el páncreas de estos 
ratones puede ser una consecuencia de la falta específica de activación de 
TGF-β1 latente en estos tejidos, requerida para la homeostasis epitelial normal 
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Una de las principales funciones de TGF-β es mantener la tolerancia de 
las células T a autoantígenos a través de la inhibición directa de la 
diferenciación de linfocitos T cooperadores (Th1 y Th2), y linfocitos T citotóxicos 
(CTL) y el mantenimiento de células T reguladoras (Treg) (112).  La 
proliferación de células asesinas naturales humanas también está regulada por 
la activación de TGF-β1 latente mediada por TSP1 (113).  En un principio, TGF-
β1 está enmascarado por la asociación no covalente con un dímero de su 
propéptido N-terminal, denominado proteína asociada a latencia (LAP) (114, 
115).  Los TSRs centrales de la TSP1 interaccionan con la región N-terminal de 
LAP formando un complejo de tres moléculas (116).  En este complejo tiene 
lugar un cambio conformacional que hace que TGF-β1 esté accesible a su 
receptor (77).  Además la TSP1 parece tener un papel dominante en la 
activación de TGF-β1 latente especialmente en los pulmones y el páncreas.   
 
La TSP1 también regula de forma directa la fisiología de las células T.  
Estudios basados en el uso de microarrays de cDNA indican que TSP1 es 
fundamentalmente un inhibidor de la transducción de señales vía TCR (117), 
aunque algunos péptidos muestran actividades diferentes a las de la proteína 
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Los TSRs de TSP1 se unen a HSPG en células T y estimulan la 
activación del oncogén Ras inducida por CD3 así como la fosforilación en 
tirosinas de las tres MAP kinasas Erk1/2, JNK y p38 (118).  Para analizar el 
papel de los receptores de TSP1 en estas funciones se usaron líneas celulares 
de células T con mutaciones somáticas que las hacen deficientes en integrinas 
de tipo β1 o en CD47 (119).  Estos estudios indicaban que la integrina α4β1 es 
necesaria y suficiente para estimular la adhesión de células T, y también para la 
estimulación de quimiotaxis y expresión génica de MMPs mediada por TSP1 y 
TSP2 (119).  Estos autores ya habían visto previamente que el receptor CD47 
juega un papel significativo en la inhibición de la señalización vía TCR y en la 
proliferación de células T (117), así como en la inhibición de la diferenciación de 

















Figura 5.  Transducción de señales por Trombospondina-1 en linfocitos T  
(Kuznetsova, S.A., et al., 2004)
Los ratones nulos para CD47 presentan defectos en la movilidad de los 
leucocitos y en las respuestas frente a bacterias patógenas (122).  Este fenotipo 
está en consonancia con evidencias de que CD47 controla la activación de 
α4β1 (123), requerida para la diapédesis de leucocitos en respuesta a algunas 
señales inflamatorias.  La TSP1 también puede regular las funciones de las 
células T indirectamente, a través de sus efectos en células presentadoras de 
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1.1.4.B. Regulación de las Respuestas Inmunes Innatas 
 
 
Las proteínas de ECM liberadas en sitios de inflamación o lesión pueden 
modular los procesos de fagocitosis, adhesión, movilidad, generación de 
oxidantes, etc mediados por leucocitos polimorfonucleares (PMNs).  Aunque el 
mayor reservorio de la TSP1 está en los gránulos α de las plaquetas también la 
secretan, aunque en menor medida, otros tipos celulares tales como, 
monocitos, macrófagos y células dentríticas (DCs). en las cuales desempeña 
diversas funciones relevantes en la fisiología de estas células fagocíticas.  La 
TSP1 procedente de monocitos apoptóticos y su HBD promueven un estado 
tolerogénico y fagocítico en DCs inmaduras (124).  En eosinófilos y neutrófilos 
senescentes la TSP1 media los procesos de fagocitosis mediada por 
macrófagos.  Esto sería un mecanismo limitante de daño asociado a la 
acumulación de deshechos celulares que implica la unión de la TSP1 a los 
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Los macrófagos median la fagocitosis de eosinófilos apoptóticos por un 
mecanismo independiente de la secreción de quimioquinas.  Por el contrario, la 
fagocitosis de eosinófilos post-apoptóticos puede desencadenar respuestas pro-
inflamatorias (126).  El proceso de fagocitosis de neutrófilos apoptóticos por 
macrófagos puede ser potenciado por citoquinas proinflamatorias tales como 
TGF-β1, y factores estimulantes de colonias de macrófagos y granulocitos (GM-
CSF), como un mecanismo de regulación del número de neutrófilos en sitios de 
inflamación (127).  El reconocimiento y la fagocitosis de fibroblastos apoptóticos 
por parte de los macrófagos depende de TSP1 procedente de los fibroblastos y 
de CD36 (128).  Además, los fagocitos semiprofesionales, tales como células 
mesangiales, median la fagocitosis de neutrófilos apoptóticos por un mecanismo 
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La TSP1 puede regular la agregación homotípica de la línea celular 
monocítica humana U937 mediada por el antígeno asociado a función 
leucocitaria (LFA-1) y por la molécula de adhesión intracelular (ICAM-1) a través 
de su efecto inhibidor vía CD47 o de su efecto activador vía CD36 (130).  Por 
otro lado, la TSP1 desempeña un papel fundamental en inflamación y 
aterogénesis al aumentar la adhesión de monocitos al endotelio, mecanismo 
que conlleva la inducción de la molécula de adhesión vascular (VCAM-1) y de la 
molécula de adhesión intracelular ICAM-1 (131).  A concentraciones elevadas, y 
en solución, la TSP1 estimula la movilidad de neutrófilos humanos (132, 133) y 
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Además, la TSP1 puede desempeñar un papel en la diferenciación de 
leucocitos así como en la expresión de citoquinas.  En este sentido estaría 
implicada en la diferenciación de la línea celular de leucemia mieloide HL-60 
inducida por ácido retinoico (135).  La unión a CD47 del péptido derivado de 
TSP1, 4N1K, durante la diferenciación de monocitos en DCs, reduce la 
expresión de la IL-12 y del TNF-α (136).  De esta manera, la TSP1 procedente 
de DCs sirve de regulador negativo y contribuye a la paralización de la 
producción de citoquinas, resolución de la inflamación y mantenimiento del 
steady state (125, 137).  Pacientes deficientes en CD36 presentan respuestas 
defectuosas en la activación de NF-κB inducida por la lipoproteína de baja 












                                                                                                      Thrombospondin-1 
 
 
La TSP1 modula la expresión de IL-6 e IL-10 por parte de los monocitos 
(139) y la activación de TGF-β latente (77).  Además, mediante su unión a 
neutrófilos humanos a través de los residuos F16-G33 y A784-N823 (140), 
potencia el respiratory burst  inducido por citoquinas (141) y la generación de 
anión superóxido (O2-) inducida por el factor quimiotáctico n-formyl-methionyl-
leucyl-phenylalanine (FMLP) en neutrófilos humanos a través de su dominio N-
terminal (140, 142).  No obstante, el mecanismo fundamental en la regulación 
de la generación de O2- no ha sido identificado.   
 
En esta tesis se aportan evidencias de que TSP1 en solución causa un 
aumento significativo en la generación de O2- estimulada con phorbol 12-
myristate 13-acetate (PMA) en monocitos humanos diferenciados con 
interferon-γ (INF-γ), por interacción de la región N-terminal de la TSP1 con su 
receptor de tipo integrina α6β1.  Además hemos observado que este fenómeno 
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1.1.4.C. Regulación de la Respuesta Inmune Innata mediada por 
Macrófagos en contra del tumor  
 
 
Los macrófagos son células efectoras importantes en la respuesta 
inmune innata en contra de tumores.  No obstante, los macrófagos asociados a 
tumores (TAMs) pueden adquirir un fenotipo citotóxico (M1) o promotor del 
creciemiento tumoral (M2).  Por otra parte se ha visto que el proceso de 
diferenciación de los TAMs depende del microambiente del tejido (143).  Los 
macrófagos se activan por la vía clásica y adquieren un fenotipo M1 en 
respuesta a IFN-γ sólo o en concierto con productos procedentes de microbios.  
También se activan por la vía alternativa y adquieren un fenotipo M2 en 
respuesta a la estimulación con IL-4 o IL-13, IL-10, IL-21, TGF-β, 
inmunocomplejos y glucocorticoides (144).  En general, los macrófagos M2 
están presentes en tumores establecidos y promueven la progresión del tumor 
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La TSP1 a menudo se regula negativamente durante la progresión 
tumoral e inhibe el crecimiento tumoral cuando se re-expresa.  Esta actividad 
se atribuye normalmente a la inhibición de la angiogénesis, pero los resultados 
presentados a continuación sugieren que debemos tener en cuenta los efectos 
en la inmunidad tumoral.  El presente estudio pone de manifiesto la importancia 
de la TSP1 como modulador positivo de la inmunidad innata anti-tumoral 
aumentando el reclutamiento de macrófagos y estimulando la citotoxicidad 


























Thrombospondins (TSPs) are an evolutionary ancient family of 
multidomain, calcium-binding, secreted glycoproteins, present in both 
protostome (e.g. Drosophila melanogaster, Anopheles gambiae) and 
deuterostome animals (e.g vertebrates).  Five TSPs are encoded in the human 
genome (TSP1 through TSP5), and four to five TSPs have been identified in 
other vertebrates (i.e. mouse, chicken, Xenopus laevis, Danio rerio) (1).  There 
are two major subclasses of TSPs, -A, and -B according to their assembly as 









REGULATION OF INNATE IMMUNE RESPONSES 
 
 
The subclass-A (TSP1 and TSP2) form trimers of subunits that are 
composed of an N-terminal domain, an oligomerization domain, a von 
Willebrand Factor type C (VWC) domain, three properdin-like repeats or 
thrombospondin type 1 repeats (TSRs), and a signature domain comprising 
three epidermal growth factor (EGF)-like repeats, a calcium binding wire and a 
lectin-like C-terminal globe (Figure 1) (3).  The subclass-B (TSP3-5 and 
arthropod TSPs) form pentamers, lack VWC modules and TSRs, and have 
additional EGF-like repeats (Figure 1) (3).  All TSPs share a highly conserved 












Figure 1.  Modular structures of Thrombospondin family members 
(Modified from Carlson, C.B., et al., 2008) 
Color code: N-terminal domain (red), oligomerization domain (orange), a von Willebrand 
Factor type C (VWC) domain (yellow), three properdin-like repeats or thrombospondin repeats 
(TSRs) (shades of green), three epidermal growth factor (EGF)-like repeats (shades of blue-
green, with predicted or known calcium-binding repeats colored in the darkest shade), a 
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TSPs are expressed in vertebrates during embryonic development and 
in adult tissues with a specific spatiotemporal pattern of expression (Table 1).   
 
 
Protein Embryonic Adult References
Major sites of expression *
TSP1 Widespread, especially heart, lung,
intestinal epithelium, skeletal muscle
(m), CNS, cartilage (ch)
Platelet α-granules, activated
endothelium, monocytes (h, m), corneal




Corless et al. 1992; Hiscott et al.
1997; Iruela-Arispe et al. 1993;
O'Shea et al. 1988; Tooney et al.
1998; Tucker et al. 1997; Urry et
al. 1998; Wight et al. 1985;
Hiscott, et al. 1992; Fauvel-
Lafeve, et al. 1996
TSP2 Cartilage (ch, h, m), tendon (ch),
adrenal, skeletal muscle, kidney (m)
Adrenal cortex (b, m), Leydig and
Purkinje cells, marrow stomal cells (m),
cartilage, conective tissues (h)
Adolph et al. 1999; Danik et al.
1999; Iruela-Arispe et al. 1993;
Kyriakides et al. 1998; Tooney et
al. 1998; Tucker et al. 1993;
Bornstein et al. 2004
TSP3 CNS, spinal cord, lung, bone (ch,
m), kidney (h), notocord (x)
Endocrine, kidney, uterus, muscle (h),
CNS, gut, lung (m)
Adolph et al. 1999; Iruela-Arispe
et al. 1993; Tucker et al. 1997;
Urry et al. 1998; Qabar et al.
1994
TSP4 Early osteogenesis, cornea (ch),
somites, skeletal muscle (x),
developing retina (h)
Heart, skeletal muscle, extracellular
matrix of the CNS, eye (h),
neuromuscular junctions (h, m),  tendon
(h, b), cerebellum, retina (m)
Arber et al. 1995; Hauser et al.
1995; Lawler et al. 1993;Tucker
et al. 1995; Urry et al. 1998;




Articular cartilage (m, p) Articular cartilage, tendon, synovium (p,
b, m, h), testis (m), arteries (h)
DiCesare et al. 1994,1995;
Franzen et al. 1987; Kipnes et al.
2000; Riessen et al. 2001;
Hedbom et al. 1992; Sodersten
et al. 2005  
 
Table 1.  Major sites of expression of Thrombospondins 
(Modified from Adams, J.C., et al., 2001) 
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Most adult tissues express at least one TSP, however, within a given 
tissue, individual family members are often expressed in non-overlapping cell 
populations.  However, major changes occur during pathophysiological 
conditions.  TSP1 is released from platelets α-granules; it accumulates in 
atherosclerotic lesions, and rheumatoid synovium.  TSP1 and TSP2 are highly 
expressed by stromal fibroblasts and endothelial cells within tumors during 
tumor progression (4), maybe as a host anti-tumor defense mechanism (5), and 
during the tissue remodeling in healing wounds in skin, muscle, and the central 
nervous system through expression by macrophages or microglia, fibroblasts, 
and endothelial cells.  Aberrant wound healing and prolonged persistence of 
inflammation is observed in double-TSP1/TSP2 null mice (6).  TSP3 is highly 
expressed in metastatic osteosarcoma (7).  TSP4 is differentially expressed in 
invasive lobular breast carcinoma as compared to ductal breast carcinoma (8).  
The TSRs of TSP1 and TSP2, have been shown to at least impact their anti-
angiogenic activity.  Thus, TSP3, 4 and 5, that lack TSRs, would not be 
expected to inhibit angiogenesis in the tumor microenvironment.  TSP4 
transcripts are also upregulated in the skeletal muscle of Duchene muscular 
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TSP5/COMP (cartilage oligomeric matrix protein) and COMP fragments in 
diseased cartilage, serum and synovial fluid have been correlated with 
osteoarthritis, joint injury and cartilage degradation (10, 11).   
 
TSP1 and TSP2 are the two members of this family that have been most 
intensively studied in terms of protein synthesis and degradation.  TSP1 gene 
expression is regulated at the transcriptional level through multiple binding sites 
within the 5’ flanking region of TSP1 gene in response to multiple extracellular 
stimuli (12-14).  A post-transcriptional control of mRNA stability is also involved 
in the regulation of the gene (14, 15).  Moreover, epigenetic mechanisms such 
as hypermethylation of CpG islands around the transcription start site are also 
involved in the silencing of TSP1 expression in cancer (16, 17).  Hypoxia may 
also modulate epigenetic mechanisms as well as directly or indirectly influence 
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Extracellular TSPs can be degraded extracellularly, intracellularly, or be 
retained within the extracellular matrix (ECM).  During fibrinolysis and clot 
resolution, TSP1 is a substrate for cleavage by thrombin and Factor XVIIIa.  
TSP1 is also a substrate for the cathepsins and elastases released by 
leucocytes and neutrophils during an inflammatory response (22).  TSP5 is a 
substrate for metalloproteinases (MMPs) 19 and 20 and ADAMTS (membrane 
proteins containing a disintegrin and a metalloproteinase with TSPs motifs) (23, 
24).  TSP1 and TSP2 are also degraded intracellularly through endocytosis and 
lysosomal degradation.  The rapid endocytic uptake is mediated by interactions 
of the TSP N-terminal domain with heparan sulphate proteoglycans (HSPG) and 
the low-density lipoprotein (LDL) receptor-related protein (LRP), in a complex 
with calreticulin (25).  TSPs can also undergo retention within ECM.  ECM 
retention is a conserved property of TSPs, and the mechanism of retention with 
regard to TSP1 involves the trimeric form of the C-terminal domain, the RGD 














TSP1 is the first member of this family described by Baenziger et al. in 
1971 (27), and is the one that has been most intensively studied.  This ECM 
glycoprotein was termed TSP because it was identified as a glycoprotein 
released from α-granules of platelets in response to stimulation with thrombin 






The complex nature of TSPs makes solving the structure of entire 
molecules impossible by nuclear magnetic resonance (NMR) and very difficult 
by X-ray crystallography.  The problem has been solved by studying 
recombinant fragments of TSPs.  These structures provide a working model for 












Figure 2.  Model of the complete structure of Thrombospondin-1 and 
Thrombospondin-2 
(Modified from Carlson, C.B., et al., 2008) 
Color code: N-terminal domain 
(red), oligomerization domain 
(orange), a von Willebrand 
Factor type C (VWC) domain 
(yellow), three properdin-like 
repeats or thrombospondin 
repeats (TSRs) (shades of 
green), three epidermal growth 
factor (EGF)-like repeats 
(shades of blue-green, with 
predicted or known calcium-
binding repeats colored in the 
darkest shade), a calcium 
binding wire (blue), and a lectin-
like C-terminal globe (purple), 
calcium ions (red spheres), 
signature domain sugars (green 
Corey-Pauling-Kultin (CPK) 
sticks), possible sites of 
structural flexibility (black), sites 
of co-translational modifications 
(red), and post-translational 
modifications (blue) (Carlson, 
C.B., et al., 2008). 
 
 
1.1.1. A. N-terminal domain 
 
 
Homology-searching algorithms based on structure, placed the N-terminal 
domain of TSP1 in the concanavalin A-like lectins/glucanases superfamily (29).  
The globular β-sandwich structure has 13 antiparallel β-strands, and 6 α-helices.  
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There is an additional α-helix located near the C-terminal end of the 
domain.  This helix contains Cys214, which forms a disulfide bond with Cys153 
found in the β11-β12 loop. This disulfide bond brings the C terminus into a close 




Figure 3.  Crystal structure of the N-terminal domain of Thrombospondin-1  
(Carlson, C.B., et al., 2008) 
 
Crystal structure and binding sites are 
are colored as follows: heparin-binding 
region (blue CPK sticks), fibrinogen 
and a4b1 binding sites (green), 
calreticulin binding site (orange), b13-
b14 loop covering potential 
carbohydrate-binding cleft (yellow), 
disulfide bond (CPK sticks). 
1.1.1. B. Trimeric oligomerization domain 
 
 
The structure of the trimeric oligomerization domain has not been solved.  
However, the structure of the trimeric oligomerization domain of matrilin-1 
(chicken cartilage matrix protein), provides insight into the structure of this 
domain of TSP1 and TSP2 (30).   
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The core of the domain is hydrophobic and may be rigid.  The surface of 
the domain is hydrophilic and relatively disordered.  The linkage between the N-
terminal module and the oligomerization domain (25 residues), and the linkage 
between the oligomerization domain and the VWC module (11-17 residues) are 
sites of flexibility and protease sensitivity (31).   
 
 
1.1.1. C. von Willebrand Factor type C domain 
 
 
TSP1 and TSP2 contain a single VWC module, also known as chordin-
like cysteine-rich repeat, or N-terminal fibrillar pro-collagen module.  The atomic 
structure of this module has not been solved.  However, insights can be gained 
from low resolution biophysical studies of the VWC module of TSP1 (32).  The 
VWC domain contains 10 cysteine residues, which do not have high sequence 
conservation, with some exceptions at the second and eighth cysteines (33).  
Mass spectrometry analysis of the VWC of TSP1 revealed that this module is 
glycosylated and that all the cysteine residues are involved in disulfide bonds 
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1.1.1. D. Thrombospondin repeats 
 
 
TSP1 and TSP2 contain three tandem TSRs.  TSRs (about 60 amino 
acids long) are conserved over evolution, and contain around 12 conserved 
residues comprising 6 cysteines, 2 conserved arginine residues, and 2 to 3 
tryptophan residues separated by 2 to 4 amino acids (34, 35).  Two unsual types 
of glycosylation have been recognized in  
the TSRs.  C-mannosylation of tryptophan residues is co-tranlational and is 
mediated by dolichol-P-mannose.  It occurs within the TSR WXXW sequence 
(36).  O-fucosylation is a post-translational modification mediated by O-
fucosyltransferase-2 that occurs within the CSX(S/T)C sequence of TSRs 
(serine or threonine residues) (37), and it is critical for protein maturation and 
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1.1.1. E. Signature domain 
 
 
This portion of the protein includes the tandem EGF-like repeats, 13 Ca2+ 
binding repeats comprising the Ca2+-binding wire, a C-terminal lectin-like 
module.  The largest difference in the signature domains among TSPs is in the 
number of EGF-like repeats (3 in TSP1 and TSP2) (1).  EGF1 contains a site 
that is modified by a glucose-xylose disaccharide in bovine TSP1.  EGF2 binds a 
single Ca2+ at the interface between EGF1 and EGF2 and likely stabilizes the 
interactions between the modules.  EGF3 has interaction with EGF2, the N- and 
C-terminal portions of the Ca2+-binding wire, and the lectin-like module.  The 
Ca2+-binding wire forms a stable, Ca2+-dependent structure that is independent 
of the rest of the signature domain and transmits allosteric changes induced by 
Ca2+ ions to other parts of TSPs (3, 39).  The Ca2+-binding wire comprises 13 
aspartate-rich repeats that form individual globular folds connected in a disulfide-
stabilized arrangement.  On average, each repeat binds two Ca2+ ions.  Ca2+ 
binding causes a conformational change (40), and keeps the signature domains 
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The lectin-like module is composed of two β-sheets (each comprising 
seven β-strands).  Of the two β-sheets, one has a convex curve on the surface 
of the protein and the other has a more severe bend toward the interior of the 
protein.  A short α-helix lies within the cleft formed by the second β-sheet.  
Homology-searching algorithms based on structure, placed this module in the L-
type lectin domain family. 
 
 
1.1.2.Major sites of expression 
 
 
TSP1 is expressed in various adult and developing tissues with a 
complex pattern.  However, the major changes occur during pathophysiological 
conditions.  TSP1 is rapidly and transiently released at high concentrations in 
response to tissue injury (6, 41).  TSP1 is expressed in healing wounds of skin, 
skeletal (42), muscle, nerve (43, 44), atherosclerotic lesions, and intimal 
hyperplasia (45, 46).  TSP1 is expressed in the hemostatic plug with a unique 
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TSP1 is elevated in some chronic coronary artery diseases (48).  TSP1 is 
expressed by corneal and iris fibroblasts in pseudoexfoliation syndrome (49).  
TSP1 is abundantly expressed in the rheumatoid synovium (50).  TSP1 is highly 
expressed by stromal fibroblasts and endothelial cells within tumors during the 
early stages of tumor progression (4), maybe as a host anti-tumor defense 
mechanism (5).  However, TSP1 expression is frequently lost during tumor 
progression.  This is due to positive regulation by tumor suppressors such as 





















TSP1 binds to other extracellular molecules such as matrix components, 
proteases, cytokines, and growth factors.  TSP1 also binds to transmembrane 
glycoproteins that can serve as signalling receptors for TSP1.  The binding sites 
for these receptors have been mapped using synthetic peptides.  The N-terminal 
domain of TSP1 contains consensus high-affinity BBXB heparin/HSPG-binding 
motifs.  The TSRs contribute to heparin binding with multiple lower-affinity sites 
(55, 56).  TSP1 also binds decorin (57), activated α3β1, α6β1, α9β1, and α4β1 
integrins (3, 58-60), fibrinogen (29), calreticulin (3), and LRP (61) through the N-
terminal domain.  The TSRs mediate interactions of TSP1 with CD36 (62, 63), 
β1 integrins (64, 65), fibronectin (66), matrix metalloproteinase 2 (MMP-2) (67), 
and TGF-β1 (68).  The WSHWSPW motif in the second type 1 repeat of TSP1 
binds to the latent TGF-β1.  Mature active TGF-β1 is then released by an 
intermolecular activation effect of the KRFK motif in the first type 1 repeat of 
TSP1 (68).  This interaction with TGF-β1 is relevant for the homeostatic function 
of TSP1.  The wire of TSP1 contains binding motifs for αvβ3 and αIIbβ3 integrins 
(69), cathepsin G, and neutrophil elastase (70).  The C-terminal lectin-like 
module of TSP1 contains the CD47-binding site (71).   
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Often, the binding of TSP1 modulates the activity of the binding partner. 
For example, binding of TSP1 to neutrophil cathepsin G, and elastase, or MMP-
2 decreases the catalytic activity of these enzymes.  This process may be 
important in collagen fibrillogenesis and the regulation of angiogenesis.   
 
Differential expression or activation of cell surface receptors for TSP1, 
including integrins, CD36, CD47, LRP, proteoglycans, and sulfatides, may 
dictate the specific responses of each cell type to TSP1 (72-74). 
 
 
1.1.4.Roles of Thrombospondin-1 
 
 
Gene knockout mice and human genetic diseases provide evidences of 
the context-specific roles of TSP1 in vivo.  Mice null for TSP1 were described in 
1998 (75).  TSP1 gene knockout mice are fertile and capable of normal 
development.  However, the embryonic viability is decreased, and the 
phenotypes include pneumonia (from 1 month of age), a mild spinal lordosis, 
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The pneumonia, and abnormal inflammation in the lungs and pancreas of 
TSP1-null mice have many phenotypic similarities with those of TGF-β1-null 
mice (76), and are a consequence of a specific lack of TGF-β1 activation in 
these tissues.  Although TSP1 is not the only activator of TGF-β1, it seems to 
have a dominant role in TGF-β1 activation in these two tissues, required for 
normal epithelial homeostasis and control of immune responses (77).  Besides 
these minor defects, the null mice appear relatively normal.  However, additional 
functions of TSP1 have been recently revealed by subjecting these mice to 
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Functional studies revealed that TSP1 has many effects on cell function, 
including adhesion, cytoskeletal organization, migration, neurite outgrowth, cell-
cell aggregation, proliferation, apoptosis, differentiation, and transcriptional 
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TSP1 supports the attachment of many cell types.  After the attachment, 
the cells can either remain round and static or spread and become motile.  Cell 
spreading and migration on TSP1 substrata are associated with an organization 
of the cortical cytoskeleton that involves the formation of large lamellipodia (79).  
The effects of TSP1 on the actin cytoskeleton are diverse and cell-type 
dependent.  Glomerular mesangial cells, monocytes, neutrophils, smooth 
muscle, skeletal myoblasts, and carcinoma cells, are some examples of cells 
that spread and are motile on TSP1.  The effects of TSP1 in vascular smooth 
muscle cells (VSMC) motility are relevant in the context of atherosclerotic 
lesions and vascular injury.  VSMC chemotaxis to TSP1 depends on CD47, αv-
type integrin (80), and β1 integrins (81).  Treatment of injured arteries with 
antibody to the CD47-binding site of TSP1 reduces neointimal thickening (82).  
In addition, polymorphisms in TSP1, TSP2 and TSP4, increase the risk for 
premature coronary artery disease, presumably due to an increased 
proatherogenic or prothrombotic activity (83).  However, examination of larger 
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Moreover, TSP1 potently antagonizes nitric oxide (NO)-driven VSMC 
relaxation, suggesting a role for TSP1 in controlling tissue blood flow (85).  After 
acute ischemic injury, TSP1- and CD47-null mice show increased tissue survival 
(86, 87).  TSP1 also promotes cell-cell adhesion or aggregation.  TSP1 
participates in the attachment of malarial-parasitized red blood cells (RBCs) to 
vascular endothelium (88).  TSP1 binds directly to sickle RBCs (89) and 
participates in the adhesion of sickle RBCs to endothelial cells in vitro (90), 
contributing to the pathogenesis of vaso-occlusion in sickle disease.  In addition, 
TSP1 plays a role in platelet function (platelet aggregation and fibrin clot 
formation).  One pathway through which TSP1 modulates platelet function is by 
preventing von Willebrand factor degradation by the plasma protease ADAMTS-
13.  This manifests as defective thrombus adherence in TSP1-null mice (91).  A 
second pathway through which TSP1 modulates platelet function is by 
antagonizing the physiological anti-thrombotic activity of NO (92).  NO plays an 
important role in limiting the aggregation of platelets (93).  TSP1, and 
recombinant fragments from the type 1 repeats and the C-terminal domain, 
inhibit the NO-stimulated delay in aggregation by a mechanism that involves 
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The effects of TSP1 on cell proliferation are also cell-type specific.  For 
example, TSP1 synergizes with growth factors such as EGF or PDGF to 
promote proliferation of SMC (94).  For endothelial cells, TSP1 inhibits 
proliferation and actively induces apoptosis (95-97).  CD36 is proposed to be a 
critical receptor because TSP1 does not show anti-angiogenic activity in the 
cornea in a CD36-null mouse model (98).  However, the avascular cornea is a 
specialized tissue that is maintained by high expression of soluble vascular 
endothelial cell growth factor (VEGF) receptor-1 (99).  This environment is 
permissive for fibroblast growth factor (FGF)-2 driven angiogenesis which is NO-
independent, but not for NO-mediated VEGF angiogenesis.  In contrast to the 
cornea, vascular outgrowth from CD36-null muscle explants remains sensitive to 
inhibition by TSP1 (87).  Therefore, additional TSP1 receptors mediate this 
activity (100).  Peptide motifs adjacent to the CD36-binding site also inhibit 
angiogenesis.  These peptide motifs might enhance the binding of TSP1 to 
CD36, or could have indirect effects such as sequestration of pro-angiogenic 
factors (97, 101, 102).  Although the interaction of TSP1 with CD36 plays a 
significant role in the anti-angiogenic activity of TSP1, CD36-independent 
mechanisms have also been identified.  The TSRs can bind β1 integrins (64) 
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CD47 has been reported to correlate with increased endothelial cell 
apoptosis (104).  CD47 binding peptides from the signature domain of TSP1 
also inhibited angiogenesis in the mouse cornea (105).  Vascular outgrowth from 
CD47-null muscle explants was not inhibited by TSP1, indicating that CD47 is 
necessary for an anti-angiogenic response to TSP1 in this assay (106).  
Furthermore, TSP1 and recombinant domains did not inhibit NO signalling in 
CD47 null endothelial cells.  Finally, angiogenesis of full thickness skin grafts is 
enhanced in TSP1 null and CD47 null mice but not in CD36 null mice (107).  
Therefore CD47, not CD36, is the essential TSP1 receptor for inhibiting 
angiogenesis in ischemia. 
 
In addition, TSP1 inhibits angiogenesis through effects on VEGF 
bioavailability.  TSP1 suppresses the release of VEGF from the ECM by 
inhibiting the activation of MMP-9 (108).  TSP1 also binds directly to VEGF and 
mediates its uptake and clearance (109).  TSP1 activates latent TGF-β in the 
tumor microenvironment (110), and this activity may also contribute to tumor 
dormancy.  TSP1 is often down-regulated during tumor progression (111) and 
this loss is linked to alterations in specific oncogenes and tumor suppressor 
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1.1.4.A. Regulation of Immune Responses 
 
 
TSP1-null mice display a phenotype that includes acute and chronic 
inflammatory pulmonary infiltrates, and an elevated number of circulating white 
blood cells (77), suggesting an anti-inflammatory role.  As previously described 
in page 53, the pneumonia and abnormal inflammation in the lungs and 
pancreas of TSP1-null mice may be a consequence of a specific lack of latent 
TGF-β1 activation in these tissues, required for normal epithelial homeostasis 
and control of immune response (77).  One main function of TGF- β is to 
maintain T cell tolerance to self via its direct inhibition of T helper 1 (Th1), Th2, 
and cytotoxic T lymphocyte (CTL) differentiation and the maintenance of 
regulatory T (Treg) cells (112).  Human natural killer cell proliferation is also 
regulated by TSP1-mediated activation of latent TGF-β1 (113).  TGF-β1 is 
initially masked by its non-covalent association with a dimer of its N-terminal 
propeptide, called latency-associated protein (LAP) (114, 115).  TSP1 seems to 
have a dominant role in latent TGF-β1 activation, especially in the lungs and 
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The central type I repeats of TSP1 (116) interact with the N-terminal 
region of LAP, forming a trimolecular complex.  Within the complex, a 
conformational change takes place and makes TGF-β1 accessible to its receptor 
(77).   
 
In addition, TSP1 directly regulates T cell function.  Studies using cDNA 
microarrays indicate that intact TSP1 is predominantly an inhibitor of T cell 
antigen receptor (TCR) signal transduction (117), although some peptides show 
different activities from that of intact TSP1.  Type I repeat domains from TSP1 
bind to HSPG on T cells and stimulate CD3-induced Ras activation and tyrosine 
phosphorylation of the three MAP kinases Erk1/2, JNK, and p38 (118).  Somatic 
mutant T cell lines deficient in either β1 integrins or in CD47 were used to 
dissect the functions of these TSP1 receptors (119).  α4β1 integrin is necessary 
and sufficient for stimulation of T cell adhesion, and it is also required for 
stimulation of chemotaxis and MMPs gene expression by TSP1 and TSP2 (119).  
CD47 plays a significant role in inhibiting TCR signalling and T cell proliferation 
(117), and inhibiting differentiation of naïve T cells into Th1 effectors (120) 










Figure 5.  Thombospondin-1 signal transduction in T lymphocytes  
(Kuznetsova, S.A., et al., 2004) 
CD47 null mice have defects in leukocyte motility and impaired responses 
to bacterial pathogens (122).  This phenotype is consistent with evidence that 
CD47 controls activation of α4β1 (123), required for leukocyte diapedesis in 
response to some inflammatory signals.  TSP1 may also regulate T cell function 
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1.1.4.B. Regulation of Innate Immune Responses 
 
 
ECM proteins released at the site of inflammation or injury may modulate 
polymorphonuclear leukocytes (PMNs) phagocytosis, adhesion, motility, oxidant 
generation, etc.  TSP1 is predominantly stored in platelets but also secreted at 
lower levels by many cell types including monocytes, macrophages, and 
dendritic cells (DCs).  TSP1 plays several roles in the physiological functions of 
phagocytes.   
 
Apoptotic monocytes-derived TSP1 and its HBD, lead to immature DC 
tolerogenic and phagocytic state (124).  TSP1 mediates phagocytosis of 
senescent eosinophils and neutrophils undergoing apoptosis by human 
monocyte-derived macrophages, as an injury-limiting disposal mechanism that 
involves αvβ3/CD36/TSP1 (126, 127).  Macrophages mediate phagocytosis of 
apoptotic eosinophils by a mechanism uncoupled from chemokine secretion.  By 
contrast, phagocytosis of post-apoptotic eosinophils may elicit pro-inflammatory 





                                                                                                      Thrombospondin-1 
 
 
Macrophage phagocytosis of apoptotic neutrophils can be potentiated by 
proinflammatory cytokines such as TGF-β1, and granulocyte-macrophage-
colony-stimulating factor (GM-CSF), as a negative feedback control of neutrophil 
number at inflamed sites (127).  Macrophage recognition and phagocytosis of 
apoptotic fibroblasts is dependent on fibroblast-derived TSP1 and CD36 (128).  
In addition, semiprofessional phagocytes such as mesangial cells mediate 
phagocytosis of apoptotic neutrophils by a mechanism dependent of αvβ3/TSP1, 
independent of CD36, and uncoupled from chemokine secretion (129). 
 
TSP1 may regulate leukocyte function associated antigen (LFA)-
1/intracellular cell adhesion molecule-1 (ICAM-1)-mediated homotypic 
aggregation of human monocytic U937 cells by either the inhibitory effect via 
CD47 or the promoting effect through CD36 (130).  Moreover, TSP1 plays a 
crucial role in inflammation and atherogenesis by increasing monocyte 
attachment to endothelium.  The mechanism involves up-regulation of vascular 
cell adhesion molecule-1 (VCAM-1) and ICAM-1 (131).  Soluble TSP1 at high 
concentrations stimulates motility of human neutrophils (132), (133) and 
promotes chemotaxis and haptotaxis of human peripheral blood monocytes 
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TSP1 may play a role in leukocyte differentiation and cytokine expression.  
TSP1 is involved in retinoic acid-induced differentiation of HL-60 myeloid 
leukemia cells (135).  Ligation of CD47 by the TSP1-derived peptide 4N1K 
during monocyte differentiation into DC, reduces interleukin (IL)-12 and tumor 
necrosis factor-α (TNF-α) expression (136).  Thus, DC-derived TSP1 serves as 
a negative regulator contributing to arrest of cytokine production, resolution of 
inflammation, and maintenance of steady state (125, 137).  CD36-deficient 
patients have impaired response of oxidized low density lipoprotein (LDL)-
induced NF-κB activation and subsequent cytokine expression (138).  TSP1 
modulates expression of IL-6 and IL-10 by monocytes (139) and activation of 
latent TGF-β (77).  In addition, TSP1 binds to human neutrophils through the 
residues F16-G33 and A784-N823 (140), enhances cytokine-induced respiratory 
burst of human neutrophils (141) and enhances chemoattractant n-formyl-
methionyl-leucyl-phenylalanine (FMLP)-mediated superoxide anion (O2-) 
generation from human neutrophils through its N-terminal domain (140, 142).  
However, the underlying mechanism for regulation of O2- generation has not 
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Here, we provide evidence that soluble TSP1 causes a significant 
increase in phorbol 12-myristate 13-acetate (PMA)-mediated O2- generation 
from interferon- γ (INF-γ)-differentiated human monocytes by interaction with its 
receptor α6β1 integrin through its N-terminal region and identify a requirement 
for and extracellular calcium (Ca2+) to mediate the macrophage respiratory burst.   
 
 
1.1.4.C. Regulation of Macrophage-mediated Innate Immune 
Response against tumors 
 
 
Macrophages are an important effector cell of innate immunity against 
tumors.  However, tumor-associated macrophages (TAMs) can differentiate into 
either cytotoxic (M1) or tumor growth-promoting (M2) states.  This differentiation 
depends on the tissue microenvironment (143).  Macrophages are classically 
activated toward the M1 phenotype by IFN-γ alone or in concert with microbial 
products.  Alternative activation by stimulation with IL-4 or IL-13, IL-10, IL-21, 
TGF-β, immune complexes, and glucocorticoids drives macrophages toward M2 
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In general, M2 macrophages are present in established tumors and 
promote tumor progression (145).  TSP1 is often down-regulated during tumor 
progression and inhibits tumor growth when re-expressed.  This activity is 
generally attributed to inhibiting angiogenesis, but the above results suggest that 
effects on tumor immunity should also be considered.  The current study 
demonstrates an important role for TSP1 as a positive modulator of innate anti-
tumor immunity by increasing macrophage recruitment and stimulating reactive 
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El propósito de este proyecto es determinar el mecanismo por el 
cual la proteína de matriz extracelular TSP1 regula la respuesta inmune 
innata.  Numerosos estudios sugieren que la TSP1 juega un papel 
importante en el reclutamiento de monocitos y de macrófagos en tejidos 
que han sufrido algún tipo de daño y en focos inflamatorios.  Además, en 
trabajos anteriores se ha observado un aumento en el infiltrado de 
macrófagos en tumores que sobreexpresan TSP1.  Así pues, el objetivo 
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Nuestra hipótesis de partida es la siguiente: “La TSP1 podría estar 
jugando un papel relevante en la inmunidad anti-tumoral al aumentar el 
reclutamiento y la activación de los TAMs de fenotipo M1“; y se pretende 
validar respondiendo las siguientes preguntas: 
 
¿Podemos estimular el reclutamiento de los TAMs de fenotipo M1 in vivo 
mediante la sobreexpresión de TSP1?.  
¿Es la TSP1 capaz de potenciar la activación de los macrófagos de 


















B.STATEMENT OF PURPOSE 
 
 
The purpose of this study was to determine the regulation of innate 
immune responses by the ECM protein TSP1.  Since several studies 
have suggested that TSP1 plays an important role in the recruitment of 
monocytes and macrophages to sites of tissue injury or inflammation, and 
previous reports have shown that tumors over-expressing TSP1 are 
heavily infiltrated in macrophages, the role of TSP1 in macrophage 
recruitment into the tumor was investigated. 
 
The following hypothesis was tested: “TSP1 may play an important 
role in anti-tumor immunity by enhancing recruitment and activation of M1 
TAMs”, by asking the following relevant questions. 
 
Does TSP1 over-expression stimulate M1 TAMs recruitment in vivo? 
Can TSP1 enhance activation of M1 macrophages (tumor cytotoxicity, 



































Gema Martin-Manso, Susana Galli, Lisa A. Ridnour, Maria Tsokos, 
David A. Wink, and David D. Roberts.  Thrombospondin1 promotes 
Tumor Macrophage Recruitment and Enhances Tumor Cell 


















Thrombospondin 1 Promotes Tumor Macrophage Recruitment and











and David D. Roberts
1
1Laboratory of Pathology and 2Radiation Biology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland
Abstract
Inhibition of tumor growth by thrombospondin (TSP) 1 is
generally attributed to its antiangiogenic activity, but effects
on tumor immunity should also be considered. We show that
overexpression of TSP1 in melanoma cells increases macro-
phage recruitment into xenograft tumors grown in nude or
beige/nude mice. In vitro , TSP1 acutely induces expression of
plasminogen activator inhibitor-1 (PAI-1) by monocytic cells,
suggesting that TSP1-induced macrophage recruitment is at
least partially mediated by PAI-1. Tumor-associated macro-
phages (TAM) can either promote or limit tumor progression.
The percentage of M1-polarized macrophages expressing
inducible nitric oxide synthase is increased in TSP1-expressing
tumors. Furthermore, soluble TSP1 stimulates killing of breast
carcinoma and melanoma cells by IFN-;–differentiated U937
cells in vitro via release of reactive oxygen species. TSP1
causes a significant increase in phorbol ester–mediated
superoxide generation from differentiated monocytes by
interaction with A6B1 integrin through its NH2-terminal
region. The NH2-terminal domain of TSP2 also stimulates
monocyte superoxide production. Extracellular calcium is
required for the TSP1-induced macrophage respiratory burst.
Thus, TSP1 may play an important role in antitumor
immunity by enhancing recruitment and activation of M1
TAMs, which provides an additional selective pressure for loss
of TSP1 and TSP2 expression during tumor progression.
[Cancer Res 2008;68(17):7090–9]
Introduction
Thrombospondin 1 (TSP1) is a secreted glycoprotein that is
predominantly stored in platelets but also secreted at low levels by
many cell types, including monocytes and macrophages. TSP1 is
rapidly and transiently released in response to tissue injury and is
elevated in several chronic diseases (1, 2). TSP1-null mice display
acute and chronic inflammatory pulmonary infiltrates and an
elevated number of circulating WBCs (3), suggesting an anti-
inflammatory role. In contrast, TSP1 expression in ischemic
injuries limits tissue survival and restoration of perfusion by
blocking nitric oxide/cyclic guanosine 3¶,5¶-monophosphate signal-
ing (4). The diverse biological activities of TSP1 are mediated by its
multiple functional domains that engage corresponding receptors
expressed by a variety of cells. Differential expression or activation
of cell surface receptors for TSP1, including integrins, CD36, CD47,
low-density lipoprotein (LDL) receptor-related protein, proteogly-
cans, and sulfatides, may dictate the specific responses of each cell
type to TSP1 (5).
TSP1 plays several roles in the physiologic functions of
phagocytes. TSP1 mediates phagocytosis of neutrophils undergoing
apoptosis (6). Macrophage recognition and phagocytosis of
apoptotic fibroblasts requires fibroblast-derived TSP1 and CD36
(7). CD36-deficient patients have impaired oxidized LDL-induced
nuclear factor-nB activation and subsequent cytokine expression
(8). TSP1 modulates expression of interleukin (IL)-6 and IL-10 by
monocytes (9) and activation of latent transforming growth factor
h (TGFh; ref. 3). TSP1 stimulates motility of human neutrophils
(10, 11) and promotes chemotaxis and haptotaxis of human
peripheral blood monocytes (12). In addition, TSP1 enhances
cytokine-induced respiratory burst of human neutrophils (13) and
enhances chemoattractant fMLP-mediated superoxide anion (O2
)
generation by human neutrophils through its NH2-terminal domain
(14, 15). However, the underlying mechanism for regulation of
O2
 generation has not been delineated. Here, we provide evidence
that soluble TSP1 causes a significant increase in phorbol
12-myristate 13-acetate (PMA)–mediated O2
 generation from
IFN-g–differentiated human monocytes by interaction with a6h1
integrin through its NH2-terminal region and identify a require-
ment for extracellular calcium to mediate the macrophage
respiratory burst.
Macrophages are an important effector cell of innate immunity
against tumors. However, tumor-associated macrophages (TAM)
can differentiate into either cytotoxic (M1) or tumor growth–
promoting (M2) states. This differentiation depends on the tissue
microenvironment (16). Macrophages are classically activated
toward the M1 phenotype by IFN-g alone or in concert with
microbial products. Alternative activation by stimulation with IL-4
or IL-13, IL-10, IL-21, TGFh, immune complexes, and glucocorti-
coids drives macrophages toward the M2 phenotype (17). M2
macrophages are present in most established tumors and promote
tumor progression (18).
TSP1 is often down-regulated during tumor progression and
inhibits tumor growth when reexpressed (19). This activity is
generally attributed to angiogenesis inhibition, but the above
results suggest that effects on tumor immunity should also be
considered. The current study shows an important role for TSP1 as
a positive modulator of innate antitumor immunity by increasing
M1 macrophage recruitment and stimulating reactive oxygen
species (ROS)-mediated tumor cytotoxicity.
Materials and Methods
Proteins and peptides. Human TSP1 was purified from the
supernatant of thrombin-activated platelets obtained from the NIH
Blood Bank (20). Recombinant human TSP1 was obtained from EMP
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Genetech. Recombinant proteins containing various domains of TSP1
and TSP2 were prepared as previously described and provided by Dr. Deane
Mosher (University of Wisconsin, Madison, WI; refs. 21–23). The a6h1
integrin inhibitory peptide (LALERKDHSG) derived from TSP1 and the
control peptide (LALARKDHSG) were prepared as described (24). Xanthine,
xanthine oxidase, and superoxide dismutase (SOD) were obtained from
Stratagene.
Reagents. Rat anti-mouse CD68 antibody (clone FA-11) was from AbD
Serotec. Monoclonal neutralizing antibody (clone 9016) against human
TGFh1, recombinant human and mouse IFN-g, recombinant human TGFh1,
and recombinant human IL-4 were from R&D Systems. Rabbit polyclonal to
plasminogen activator inhibitor-1 (PAI-1) and rabbit polyclonal to inducible
nitric oxide synthase (iNOS) were from Abcam, Inc. Anti-actin (Ab-1) mouse
monoclonal antibody and EGTA were from Calbiochem. The function-
blocking rat anti-human a6 integrin monoclonal antibody (clone G0H3) was
from Chemicon International, Inc. FITC-conjugated rat anti-human a6
monoclonal antibody (clone G0H3) and the isotype control were from BD
Biosciences. Lipopolysaccharide (LPS) from Escherichia coli 0111:B4 and
PMA were from Sigma-Aldrich. The inhibitor of iNOS, aminoguanidine, was
from Sigma-Aldrich. The a4h1 integrin antagonist [4-((2-methylphenyl)ami-
nocarbonyl)aminophenyl] acetyl-LDVP (25) was obtained from Bachem. The
calcium indicator Fluo-4/AM, rabbit polyclonal anti-fluorescein/Oregon
Green, and Pluronic F-127 were from Molecular Probes.
THBS1-transfected cells. MDA-MB-435 cells transfected with the
THBS1 expression plasmid (clone TH26, 7.5-fold higher TSP1 expression
than control) or the empty pCMVBamNeo vector (Neo) were described
previously (26).
Cell culture and differentiation. Transfected MDA-MB-435 cells were
cultured at 37jC, 5% CO2, in complete RPMI 1640 (Life Technologies)
containing 10% fetal bovine serum (FBS; Biosource), 2 mmol/L glutamine,
100 units/mL penicillin, 100 Ag/mL streptomycin, and 750 Ag/mL geneticin
(Life Technologies). The human monocytic line U937 (27), kindly provided
by Dr. Mark Raffeld [National Cancer Institute (NCI), NIH, Bethesda, MD],
was cultured at 37jC, 5% CO2, in RPMI 1640 supplemented with 2 mmol/L
glutamine, 100 units/mL penicillin, 100 Ag/mL streptomycin, and
10% endotoxin-tested FBS (Biosource). For differentiation with IFN-g,
2.0  105/mL U937 cells in complete growth medium containing 1 mmol/L
sodium pyruvate, 0.1 mmol/L MEMwith nonessential amino acids (Cellgro),
and 100 units/mL recombinant human IFN-g were incubated for 3 d at
37jC. For differentiation with IL-4, 2.0  105/mL U937 cells in AIM-V +
Albumax serum-free medium (Life Technologies) containing 10 ng/mL
recombinant human IL-4 were incubated for 3 d at 37jC. MDA-MB-231,
MDA-MB-435, and MCF-7 cells were cultured in RPMI 1640 containing 10%
FBS, 2 mmol/L glutamine, 100 units/mL penicillin, and 100 Ag/mL
streptomycin. Murine macrophage cell lines ANA-1 (28) and RAW264.7
were cultured in DMEM (Life Technologies) supplemented with 2 mmol/L
glutamine, 100 units/mL penicillin, 100 Ag/mL streptomycin, and 5%
endotoxin-tested FBS. Human peripheral blood mononuclear cells (PBMC)
were prepared by gradient centrifugation. In brief, fresh human buffy
coat (NIH Blood Bank) was diluted 1:4 with sterile Dulbecco’s PBS
(Life Technologies). Human PBMCs were isolated by mixing 1.077 g/mL
Lymphocyte Separation Medium (Cambrex) and the diluted human blood
and centrifuged for 30 min at 900  g , 18jC to 20jC. Human monocytes
were isolated from PBMCs by adherence to plastic.
Tumorigenesis assay in nude mice. Groups of 10 female NIH-bg/nu
mice, f8 wk of age, were injected in the mammary fat pads with 8  105
Neo or TH26 cells. Primary tumor size was determined twice weekly by
length  width  height measurement. The primary tumors were removed
on week 11.
A total of 15 female NIH-nu/nu mice, 7 wk of age, were s.c. injected in the
right hind leg with 5  106 MDA-MB-435 cells. Five animals were injected
with Neo cells and 10 with TH26 cells. Primary tumor size was determined
twice weekly, and tumor volume was calculated as (width)2  length/2.
Primary tumors were removed when the volume was 300 to 400 mm3 or at
week 7. For histopathologic analysis, tumor tissues were fixed in buffered
formalin, embedded in paraffin, sectioned (5 Am), and stained with H&E.
Animal experiments were conducted in an accredited facility according to
NIH guidelines under a protocol approved by the NCI Animal Care and Use
Committee.
Immunohistochemical evaluation. Slides were deparaffinized in
xylene (thrice for 10 min) and rehydrated in graded alcohol (100%, 95%,
and 70%). Antigen retrieval was performed in a pressure cooker containing
Target Retrieval Solution (pH 6.10; Dako Corp.) for 30 min (CD68 antibody)
or 10 min (PAI-1 antibody) or 10 mmol/L citrate buffer (pH 6.0) for 10 min,
followed by cooling at room temperature for 20 min (iNOS antibody),
and then washed with PBS twice for 10 min. Endogenous peroxidase activity
was quenched by 0.3% H2O2 in water. After washing the slides with
Wash Buffer Solution (Dako), nonspecific binding was reduced using
Protein Block Serum-Free (Dako) for 10 min. The slides were incubated
with CD68 antibody (1:100, overnight at 4jC), PAI-1 antibody (1:250
dilution, 1 h at room temperature), and iNOS antibody (1:50, 1 h at
room temperature). Slides were then incubated with streptavidin-biotin
(Dako LSBA+ kit, horseradish peroxidase). 3,3¶-Diaminobenzidine (Dako)
was used as chromogen for 5 min, and hematoxylin was used for
counterstaining. Negative control slides omitted the primary antibody.
CD68 was located predominantly within the cells. Nuclei were negative.
Cytoplasmic and extracellular staining in macrophages was considered
positive for PAI-1. Cytoplasmic staining in macrophages was considered
positive for iNOS. The intensity of the staining was evaluated using a
Nikon Eclipse E1000 microscope equipped with a microcolor camera
(RGB-MS-C). The acquisition software was IPLab-Scientific Image
Processing 3.5.5.
Measurement of monocyte chemotactic protein-1, PAI-1, and IL-10.
Monocyte chemotactic protein-1 (MCP-1), PAI-1, and IL-10 levels in
differentiated U937 cell supernatants were measured with a multiplex
ELISA array (Quansys Biosciences). All samples were run in replicate.
Western blotting. RAW264.7 cells were serum deprived for 48 h before
addition of TGFh1 or TSP1. After 2 to 4 h of incubation at 37jC, 5% CO2, in
AIM-V + Albumax serum-free medium, cells were lysed at 4jC in 0.5%
deoxycholic acid, 0.1% SDS, 50 mmol/L HEPES, 1% Triton X-100, 1% NP40,
150 mmol/L NaCl, 50 mmol/L NaF, 1 mmol/L sodium orthovanadate,
2 Ag/mL aprotinin, 2 Ag/mL leupeptin, and 1 mmol/L phenylmethylsulfonyl
fluoride. Cell pellets were vortexed briefly and centrifuged at 14,000 rpm
for 15 min. Cell lysates (15 Ag protein) were boiled for 5 min in SDS
sample buffer, electrophoretically separated on NuPAGE 10% Bis-Tris
gels (Invitrogen) for 1.5 h at 150 V, and transferred to Immobilon-P
polyvinylidene difluoride membranes (Millipore) for 2 h at 100 V.
Membranes were blocked in 5% bovine serum albumin (BSA)/0.1%
Tween 20/PBS and incubated overnight with rabbit polyclonal to PAI-1
(2.5 Ag/mL). Enhanced chemiluminescence (Upstate) was used for
detection. Stripped membranes were reprobed with actin antibody to
confirm protein loading levels.
Real-time quantitative reverse transcription-PCR analysis. Total
RNA was extracted from Neo and TH26 tumors using Trizol (Invitrogen)
according to the manufacturer’s instructions. Total RNA was treated with
recombinant DNase I (DNA-free kit, Applied Biosystems) and quantified
using the NanoDrop ND-1000 Spectrophotometer (NanoDrop Technolo-
gies). cDNA was synthesized from total RNA using iScript cDNA Synthesis
kit (BioRad). Real-time PCR for mouse iNOS and arginase-1 expression
profiling was performed on a 7500 Real-Time PCR instrument (Applied
Biosystems) using Taqman oligonucleotide primers Mm00440485_m1 and
Mm00475988_m1, respectively. Data were normalized against mouse
hypoxanthine phosphoribosyltransferase 1 (HPRT1; Mm00446968_1). Rela-
tive iNOS and arginase-1 expression was calculated using the 2DDCT
method.
U937 and ANA-1 cell-mediated cytolysis. MDA-MB-231, MDA-MB-435,
and MCF-7 target cells were seeded into 16-well plates in 150 AL of growth
medium. Cell growth was dynamically monitored using RT-CES system
(ACEA Biosciences) for 24 h. Differentiated U937 effector cells at an E:T
ratio of 40:1 were added into wells containing target cells. ANA-1 cells were
activated for 20 h at 37jC with 10 ng/mL of LPS and 100 units/mL of IFN-g
in complete medium and also used at an E:T ratio of 40:1. After addition of
effector cells, measurements were automatically collected by the analyzer
every 10 min for up to 48 h.
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Cytotoxicity assay. MDA-MB-231 cells (2  104 per well) were seeded
into 96-well plates in 200 AL of growth medium in the presence or absence
of soluble TSP1 for up to 72 h at 37jC. MDA-MB-231 cells (2,500 per well)
were seeded into 96-well plates in 100 AL of RPMI 1640 containing 1.25%
FBS, 2 mmol/L glutamine, 100 units/mL penicillin, and 100 Ag/mL
streptomycin in the presence or absence of xanthine/xanthine oxidase for
72 h at 37jC. Media were collected to assess lactate dehydrogenase (LDH)
released due to cell death. LDH release was quantified using a colorimetric
assay (Promega). All samples were run in triplicate.
Superoxide production. O2
 levels in differentiated U937 and activated
ANA-1 cell supernatants were quantified using the LumiMax Superoxide
Anion Detection kit (Stratagene).
Flow cytometry analysis. Direct immunofluorescence was performed
by incubating 1  106 cells with 50 Ag/mL of FITC-conjugated rat
anti-human a6 antibody (clone G0H3) or isotype control for 45 min at 4jC
in HBSS containing 0.1% BSA and 0.1% sodium azide (Sigma-Aldrich). After
staining, propidium iodide was added and the cells were analyzed on a
FACScan flow cytometer (Becton Dickinson). The analysis software was
FlowJo (7.2.1).
Measurement of intracellular free Ca2+. Differentiated U937 cells
were incubated with loading solution consisting of HEPES-buffered saline
[11.6 mmol/L HEPES (Cellgro) in HBSS] supplemented with 2 Amol/L
Fluo-4, 0.02% Pluronic F-127, and 1% BSA for 30 min and then incubated in
loading solution without Fluo-4 for 30 min to allow deesterification of the
probe. Loading solution was replaced with HBSS containing anti-fluorescein
antibody and TSP1. The cells were then placed in a fluorometer (GENios
Plus Tecan), and measurements were collected every 5 min for up to 40 min.
Statistical analysis. All data are shown as mean F SD except were
indicated. Significance was determined with one-tailed distribution
Student’s t test analysis. The difference was considered significant when
P V 0.05 (*) and P V 0.001 (**).
Results
TSP1 overexpression increases tumor macrophage recruit-
ment in vivo. Expression of TSP1 in the melanoma cell line MDA-
MB-435 significantly inhibits tumor growth and metastasis (26).
Notably, increased infiltration of monocytes was observed in clone
TH26 tumors that highly express TSP1 (26) and in tumor-bearing
mice treated with TSP1 peptides (29). Because macrophage
recruitment into wounds is TSP1 dependent (1), we examined
the effect of tumor cell TSP1 over expression on TAM recruitment.
Using the previously described conditions of injection in the
mammary fat pads (26), we confirmed that TH26 tumors showed
delayed growth in female NIH-bg/nu mice relative to control-
transfected clones (data not shown). The primary tumors
were removed on week 11, and seven randomly selected mice
were analyzed by immunohistochemistry. TAMs were detectable
in nonnecrotic areas of tumor stained with H&E (data not
shown). Based on CD68 antibody staining, the percentage of TAMs
was significantly higher in TH26 tumors than in Neo tumors
(P < 0.05; Fig. 1A).
Mammary fat pad injection was used previously as an orthotopic
model of breast carcinoma growth, but recent studies have
confirmed that the MDA-MB-435 cell line is a derivative of the
M14 melanoma cell line (30). To determine whether TSP1
suppresses tumor growth at a site more appropriate for melanoma,
15 female NIH-nu/nu mice were s.c. injected in the right hind limb
with TH26 or Neo cells. TSP1 overexpression in TH26 cells also
inhibited s.c. tumor growth (P V 0.001; Fig. 1B). The primary
tumors were removed when the volume was 300 to 400 mm3 or at
week 7 and analyzed by immunohistochemistry. Sections of tumor
were stained with H&E and anti-mouse CD68 antibody. Increased
TAM infiltration was observed in s.c. TH26 versus Neo tumors
(P < 0.001; Fig. 1C and D).
Role of MCP-1 and PAI-1 in TSP1-dependent TAM recruit-
ment. MCP-1 is an important regulator of monocyte recruitment
(31), and a deficit in MCP-1 was proposed to account for decreased
infiltration of macrophages into an excisional wound of TSP1-null
mice (1). However, 12 h of stimulation with different doses
of soluble TSP1 resulted in no significant change in total
MCP-1 release from differentiated U937 human monocytic cells
(Fig. 2A, left).
Macrophage migration in vitro and in vivo also depends on
PAI-1 (32, 33), and elevated PAI-1 expression was previously
Figure 1. THBS1 overexpression promotes macrophage recruitment in
tumor-bearing nude mice. A, tissue sections cut from paraffin-embedded tumors
harvested from NIH-bg/nu mice injected in the mammary fat pads with
TH26 or Neo MDA-MB-435 clones were stained with H&E and rat anti-mouse
CD68 antibody (clone FA-11). Quantitative analysis of macrophage infiltration
into the tumor specimens was performed by evaluating the number of
CD68-positive cells per 100 field in nonnecrotic areas. The results are
presented as a percentage of TAMs in Neo control (white column ) versus
THBS1 -transfected TH26 tumors (red column ). B, primary tumor size 24 d after
injection in NIH-nu/nu mice given s.c. injections of TH26 (red column ) or Neo
cells (white column ). Histogram represents the tumor volume (mm3) of all
animals within each group that developed a tumor. C, paraffin-embedded
sections cut from clone TH26 tumors grown s.c. in NIH-nu/nu mice were stained
with H&E (top ) and rat anti-mouse CD68 antibody (clone FA-11; bottom ).
Representative photomicrographs of adjacent slides are shown from
experiments conducted in tumor samples from 12 NIH-nu/nu mice. Three mice
did not develop tumors. Identical patterns were observed in all of the tumors
examined. Magnification, 200. D, quantitative analysis of macrophage
infiltration into s.c. tumors grown in NIH-nu/nu mice was evaluated as the
percentage of CD68-positive cells in multiple 100 fields in nonnecrotic areas.
The results are presented as a percentage of TAMs in Neo (white column)
and TH26 tumors (red column ).
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reported in TH26 versus Neo cells (34). Therefore, increased
PAI-1 could also account for increased TAM recruitment into
TH26 tumors. Because this result was obtained using a stable
transfectant, it was unclear whether TSP1 directly regulates PAI-1
expression rather than the increased PAI-1 being an indirect
adaptation of the transfected clones. Incubation of differentiated
U937 cells with TSP1 resulted in an acute dose- and time-
dependent increase in PAI-1 expression, with a maximal 50-fold
Figure 2. Effects of TSP1 on MCP-1 and PAI-1 expression in differentiated U937 human monocytic cells and mouse macrophages. A to C, differentiated U937
cells (1106/0.5 mL RPMI 1640 with 0.5% FBS) were incubated in the presence or absence of soluble TSP1, soluble recombinant type 1 repeats of TSP1 (3TSR ; B ), or
soluble recombinant human TSP1 (C, right ). After 12 h of incubation (A ), or at the indicated times (B and C, right ), the supernatants were harvested, and total
MCP-1 and PAI-1 were determined using a multiplex ELISA array as described in Materials and Methods. Data are representative of at least four different experiments.
C, left, differentiated U937 cells were incubated with neutralizing TGFh1 antibody (clone 9016) for 15 min before the addition of soluble TSP1 (20 Ag/mL). Culture
supernatants collected after 12 h were used to measure total PAI-1. Data are representative of two different experiments. D, left, serum-deprived murine RAW264.7
cells were stimulated with TGFh1 (1 ng/mL), as a positive control, or soluble TSP1 (20 Ag/mL) for 2 h. The experiment was repeated thrice, and a representative anti–PAI-1
blot is shown. Actin was used to confirm equal protein loading. Right, paraffin-embedded sections cut from TH26 tumors grown s.c. in NIH-nu/nu mice were stained
with rat anti-mouse CD68 antibody (clone FA-11; left ) and rabbit anti-mouse PAI-1 antibody (right ). Representative photomicrographs of adjacent sections are shown
from experiments conducted in tumor samples from 12 NIH-nu/nu mice. Identical patterns were observed in all of the tumors examined. Magnification, 200.
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induction at 8 h [P < 0.001; Fig. 2A (right) and B]. Because PAI-1 is
a TGFh-inducible gene (35) and bioactive TGFh is present in TSP1
purified from platelets (36), we asked whether TGFh contamina-
tion or TSP1-mediated activation of latent TGFh (3) contributed
to the PAI-1 response in U937 cells. Interestingly, stimulation with
3 Ag/mL of soluble recombinant 3TSR, the type 1 repeat domain
of TSP1 responsible for the TSP1-mediated activation of latent
TGFh (37), resulted in no significant change in total PAI-1 release
from differentiated U937 cells (Fig. 2B). Therefore, activation of
latent TGFh probably does not account for the effect of TSP1
on PAI-1 expression. The NH2-terminal module of TSP1 increases
fMLP-mediated O2
 generation and chemotaxis by human
neutrophils (10, 14) but also had no effect in PAI-1 expression
(data not shown).
TSP1 stimulation of PAI-1 production was then examined in the
presence of a neutralizing TGFh1 antibody. At 5 Ag/mL, the
neutralizing antibody partially inhibited TSP1-stimulated PAI-1
production (Fig. 2C, left). Furthermore, recombinant human TSP1
at the same concentration, which should lack TGFh contamination,
showed less stimulatory activity than platelet TSP1 (Fig. 2C, right).
Therefore, bioactive TGFh present in platelet TSP1 at least partially
mediates the stimulation of PAI-1 production by TSP1, but TSP1
lacking TGFh is also active.
To address whether TSP1 also induces PAI-1 production
in mouse macrophages, we used the RAW264.7 macrophage
cell line. Increased PAI-1 expression was detected in whole-cell
lysates within 2 h after TGFh (positive control) or TSP1 treatment
(Fig. 2D, left ). Furthermore, increased PAI-1 secretion was
detected in cell culture supernatants within 4 h after TGFh or
TSP1 treatment (data not shown). We also examined whether
PAI-1 is expressed by murine TAMs in vivo . Immunohisto-
chemical analysis showed strong PAI-1 staining in the TH26
TAMs (Fig. 2D, right).
Increased M1 macrophage recruitment into TSP1-over-
expressing tumors. Activated murine macrophages metabolize
L-arginine via two main pathways that are catalyzed by the
inducible enzymes iNOS and arginase. Increased iNOS is charac-
teristic of M1 macrophages, and arginase-1 is a marker of M2
macrophages (38). To compare iNOS expression in vivo , total RNA
extracted from six randomly selected Neo and TH26 tumors was
analyzed using real-time PCR. A 3.8-fold increase in iNOS
expression was found in TH26 tumors (Fig. 3A). In contrast, the
M2 marker arginase-1 was equally expressed in both tumors
(data not shown). Staining of tumor sections using an iNOS
antibody showed an increased percentage of iNOS-expressing
TAMs in TH26 versus Neo tumors (P V 0.001; Fig. 3B and C). Taken
together, these data show that M1 cytotoxic macrophages are a
minor fraction of the TAMs in MDA-MB-435 tumors, but their
recruitment or differentiation is increased when the tumors
express TSP1.
To address whether M2 macrophage differentiation or function
is sensitive to TSP1 in vitro , U937 cells were differentiated
using IL-4 for 72 h in the presence or absence of soluble TSP1.
IL-10 levels in the cell culture supernatants, a marker of M2
polarization, showed no significant differences (Fig. 3D, left).
Similarly, incubation of IL-4–differentiated U937 cells with
soluble TSP1 (20 Ag/mL) for 12 h did not alter IL-10 secretion
(Fig. 3D, right).
TSP1 stimulates macrophage cytotoxicity toward breast
carcinoma and melanoma cells. To determine whether TSP1
can regulate tumor cell killing by macrophages, we performed
dynamic monitoring of macrophage-mediated cytolysis. IFN-g–
differentiated U937 cells were incubated with MDA-MB-231 breast
carcinoma cells (at an E:T ratio of 40:1) in the RT-CES system.
The cell index readout assesses changes in viable adherent cells
Figure 3. Increased iNOS-expressing M1 TAMs in TSP1-overexpressing
tumors. A, real-time quantitative reverse transcription-PCR analysis of mRNA
expression in TH26 and Neo tumors from six NIH-nu/nu mice. Fold difference was
adjusted to HPRT1 internal control values. Relative quantification of iNOS was
calculated by the 2DDCT method. B, immunohistochemical analysis of TH26 and
Neo tumors in NIH-nu/nu mice. Adjacent sections were stained using rat
anti-mouse CD68 antibody (clone FA-11; top ) and rabbit polyclonal antibody to
iNOS to detect M1-differentiated TAMs (bottom ). The results are representative of
tumor samples from 12 NIH-nu/nu mice, which showed identical patterns.
Magnification, 400. C, quantitative analysis of CD68-positive cells expressing
iNOS in the tumor specimens was performed by evaluating the percentage of
iNOS-positive macrophages in multiple 100 fields. The results are presented as
the percentage of iNOS-positive TAMs in Neo control (white column) and
TH26 tumors (red column ). D, left, U937 cells (2  105/0.5 mL AIM-V) were
incubated with IL-4 to induce M2 differentiation in the presence or absence of
soluble TSP1. At the indicated times, the supernatants were harvested, and IL-10
was determined using a multiplex ELISA array as described in Materials and
Methods. Right, U937 cells were differentiated with IL-4 for 72 h, and then the
differentiated cells (1  106/1 mL AIM-V) were incubated with soluble TSP1.
After 12 h of incubation, the supernatants were harvested, and IL-10 was
determined using a multiplex ELISA array.
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by electrical impedance. Differentiated U937 cells expressed
constitutive cytotoxic activity against MDA-MB-231 cells
(Fig. 4A). Moreover, tumoricidal activity was increased 5-fold
after 18 h of incubation with soluble TSP1 (5 Ag/mL; Fig. 4A, left).
This concentration of TSP1 did not show any direct cytotoxic
activity against MDA-MB-231 cells (Fig. 4A, right). TSP1 similarly
enhanced cytotoxicity against MDA-MB-435 melanoma and
MCF-7 breast carcinoma cell targets (Fig. 4B, left and right ,
respectively). Because our in vivo model used a human tumor
xenograft in mice, we also examined the mouse macrophage cell
line ANA-1 as effector against human MDA-MB-231 target cells.
Activated ANA-1 cells expressed constitutive cytotoxic activity
against MDA-MB-231 cells in the presence of an iNOS inhibitor
(0.5 mmol/L aminoguanidine) to permit O2
 accumulation (39). A
Figure 4. TSP1 increases U937 human monocytic cell–mediated tumoricidal activity. A, left, and B, MDA-MB-231, MDA-MB-435, and MCF-7 target cells
(2  104/150 AL RPMI 1640 with 10% FBS) were seeded into 16-well sensor plates and incubated for up to 24 h. After this incubation, differentiated U937 effector cells
(8  105/50 AL RPMI 1640 with 10% FBS) were directly added into wells containing target cells in the presence or absence of soluble TSP1. The measurements
were automatically collected by the analyzer RT-CES system for up to 48 h. Data are representative of three different experiments. A, right, MDA-MB-231 cells
(2  104/200 AL RPMI 1640 with 10% FBS) were seeded into 96-well plates and incubated for up to 72 h in the presence or absence of soluble TSP1 (5–20 Ag/mL). At
the indicated times, medium samples were collected and LDH released was measured as described in Materials and Methods. The absorbance was recorded at
490 nm. Data are representative of two different experiments. C, MDA-MB-231 target cells (2  104/150 AL RPMI 1640 with 10% FBS) were seeded into 16-well sensor
plates and incubated for up to 24 h. After this incubation, activated ANA-1 effector cells (8  105/50 AL RPMI 1640 with 10% FBS and 0.5 mmol/L aminoguanidine)
were directly added into wells containing target cells in the presence or absence of soluble TSP1. The measurements were automatically collected by the RT-CES
system for up to 18 h. Data are representative of four different experiments. D, MDA-MB-231 target cells (2,500/100 AL RPMI 1640 with 1.25% FBS) were seeded
into 96-well plates and incubated for 72 h in the presence or absence of different doses of xanthine (X ) and xanthine oxidase (XO ). The medium samples were
collected, and LDH released was measured. The absorbance was recorded at 490 nm. The percentage of cytotoxicity is shown above each column and is calculated as
(experimental  spontaneous/maximum  spontaneous)  100. Maximum LDH release was determined by complete lysis of target cells.
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10-fold increase in tumoricidal activity was recorded after 12 h of
incubation with soluble TSP1 (5 Ag/mL; Fig. 4C).
TSP1 has been shown to enhance chemoattractant fMLP-
mediated superoxide generation in human neutrophils (14),
suggesting that increased ROS mediates the tumoricidal activity
of TSP1-stimulated cells. To confirm sensitivity to O2
, MDA-MB-231
cells were treated with xanthine and xanthine oxidase to generate
O2
. Addition of O2
 dose dependently increased LDH release from
the cells (Fig. 4D).
TSP1 increases extracellular release of O2
. To determine
whether the known activity of TSP1 to enhance O2
 release
in human neutrophils extends to M1-differentiated U937 cells,
IFN-g–differentiated U937 cells were stimulated with PMA
(100 ng/mL), and O2
 generation was assessed using luminol
chemiluminescence. Incubation of differentiated U937 cells with
soluble TSP1 (20 Ag/mL) significantly increased (P V 0.001) PMA-
mediated O2
 production (Fig. 5A, left), and 25 units of SOD
completely abolished this signal (data not shown), confirming
that O2
 was responsible for the chemiluminescent signal. This
also indicates that TSP1 stimulates extracellular O2
 production
because SOD does not degrade intracellular O2
. Similar
enhancement of O2
 generation by TSP1 was observed in
monocytes isolated from human PBMCs and in a murine
macrophage cell line ANA-1 (Fig. 5A, middle and right). Trimeric
recombinant constructs (residues 1–356) containing the N-
modules of TSP1 (NoC1) and TSP2 (residues 1–359, NoC2) but
not other recombinant regions of TSP1 enhanced O2
 production
(Fig. 5B).
The N-module of TSP1 interacts with several receptors,
including a3h1, a4h1, and a6h1 integrins (40). Because a3h1
integrin recognizes the N-module of TSP1 but not TSP2 (41),
we examined the role of a4h1 and a6h1 integrins. Differentiated
U937 cells are known to express a4h1 (42), and we found that
they also express a6h1 (Fig. 5C). The a6h1-binding peptide
LALERKDHSG (24) and a function-blocking a6h1 antibody
partially inhibited the activity of TSP1 on O2
 generation. In
contrast, the a4h1 antagonist phLDVP had no effect. These results
identify a specific requirement for a6h1 integrin to mediate
TSP1 binding to human monocytes and the subsequent activation




 production in macrophages requires
intracellular Ca2+. Ligation of some integrins triggers a transient
elevation in intracellular free Ca2+ (43, 44). Ca2+ is a second
Figure 5. TSP1 enhances extracellular release of O2
 in
human and mouse monocytic cells. A, left, differentiated
U937 cells (5  105 per condition) were stimulated with
PMA (100 ng/mL) in the presence or absence of soluble
TSP1 (20 Ag/mL) for up to 70 min, and quantitative
analysis of O2
 levels was performed with a LumiMax
Superoxide Anion Detection kit and quantified using a
luminometer. The results are presented as the ratio
maximum activity [relative luminescence units (RLU )] per
minute. Columns, mean of five different experiments;
bars, SD. Middle, analysis of O2
 release from human
monocytic cells. Monocytes obtained from human
PBMCs (5  105 per condition) were stimulated with PMA
(10 ng/mL) in the presence or absence of soluble TSP1
(20 Ag/mL) for 30 min. The results are presented as the
ratio maximum activity (RLU) per minute. Data are
representative of four different experiments. Right,
activated ANA-1 cells (8  105 per condition) were
stimulated with PMA (100 ng/mL) and aminoguanidine
(0.5 mmol/L) in the presence or absence of soluble TSP1
(5 Ag/mL) for 130 min. The results are presented as RLU
and are representative of two different experiments.
B, analysis of O2
 release from differentiated U937 cells
(5  105 per condition) stimulated as described above in
the presence or absence of soluble TSP1 (20 Ag/mL),
NoC1, 3TSR, or E3CaG1 (10 Ag/mL) for up to 40 min.
The results are presented as a percentage of control RLU
determined in the presence of TSP1. Columns, mean of
up to four different experiments; bars, SD. C, surface a6
integrin expression in differentiated U937 cells was
analyzed using flow cytometry as described in Materials
and Methods. D, analysis of O2
 release from
differentiated U937 cells (5  105 per condition)
stimulated as described above with soluble TSP1
(20 Ag/mL) in the presence or absence of the
a4h1 integrin antagonist phLDVP (1 Amol/L), the
function-blocking rat anti-human a6 monoclonal antibody
(clone G0H3; 5 Ag/mL), p766, or control peptide (p767,
200 Amol/L) for up to 40 min. The results are presented
as a percentage of control RLU determined in the
presence of TSP1 alone. Columns, mean of up to five
different experiments; bars, SD.
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messenger for activation of NADPH oxidase in human monocytes
(45). This result suggested that increased levels of Ca2+ might
account for the enhancement by TSP1 of O2
 production in
differentiated U937 cells. Cells were loaded with Fluo-4 for 30 min
and then treated with soluble TSP1 (20 Ag/mL) for 25 to 50 min.
Addition of TSP1 caused a significant rise in intracellular free Ca2+
(Fig. 6A). This increase was eliminated completely following
chelation of extracellular Ca2+ by the addition of 1 mmol/L
EGTA (data not shown). To further confirm the role of Ca2+ in
respiratory burst activity, differentiated U937 cells were treated
with EGTA before the addition of PMA and TSP1. As shown in
Fig. 6B , chelation of extracellular Ca2+ significantly decreased the
stimulatory effect of TSP1 on PMA-mediated O2
 generation in
differentiated U937 cells, suggesting that a Ca2+-dependent
mechanism is involved in TSP1 modulation of the macrophage
respiratory burst.
Discussion
Several studies have suggested that TSP1 plays an important role
in the recruitment of monocytes and macrophages to sites of tissue
injury or inflammation (1, 12). Here, we provide evidence that
overexpression of TSP1 in tumors increases macrophage recruit-
ment in vivo . Tumor cells produce a range of chemotactic factors
for macrophages. MCP-1 stimulates recruitment of macrophages
into tumors in vivo (46), and decreased expression of these
chemokines was reported to limit infiltration of macrophages into
an excisional wound in TSP1-null mice (1). However, soluble TSP1
did not increase MCP-1 release from differentiated U937 human
monocytic cells. PAI-1 is also required for cell migration in vitro
(33), and evidence is emerging for a critical role of PAI-1 in
macrophage migration in vitro and in vivo (32). TSP1 up-regulates
PAI-1 in pancreatic cancer cells (47), and PAI-1 expression is
up-regulated in TSP1-expressing MDA-MB-435 cells (34). We
found that TSP1 acutely increased PAI-1 production by differen-
tiated human and mouse macrophages, and strong TAM
expression of PAI-1 was observed in TSP1-overexpressing tumors
in vivo . This acute change in PAI-1 expression in response to
TSP1 is at least partially TGFh mediated. Activation of latent
TGFh is mediated by the type 1 repeats of TSP1, but we found
no induction of PAI-1 by this domain. Therefore, TSP1 probably
induces PAI-1 via bound active TGFh rather than activation
of latent TGFh produced by U937 cells. Although additional
cytokines may be involved, autocrine induction of PAI-1 via
tumor cell produced TSP1 as well as paracrine induction of
PAI-1 expression in TAMs could increase macrophage recruitment
into the tumor.
Whether increased macrophage recruitment inhibits or enhan-
ces tumor growth depends on their differentiation state. The tumor
environment can educate TAMs toward a tumor-promoting
phenotype (M2; ref. 18), which may prevent further macrophage
migration within the tumor and ensure constant production of
growth and angiogenic factors. In addition to contributing to
macrophage infiltration by stimulating PAI-1 signaling in TAMs, we
found that TSP1 expression in the tumor selectively increases M1
macrophage infiltration. This may provide a selective pressure
distinct from its antiangiogenic activity to account for the
frequently observed down-regulation of TSP1 during tumor
progression and its ability to inhibit tumor growth when reex-
pressed.
In general, M1 macrophages are efficient producers of reactive
oxygen and nitrogen intermediates that mediate resistance
against tumors (17). Here, we provide evidence that tumor
expression of TSP1 increases M1 polarization of TAMs assessed
by iNOS expression. TSP1 was previously shown to enhance
cytokine-induced and chemoattractant fMLP-induced respiratory
burst in human neutrophils (13, 14). We now show that TSP1
enhances PMA-mediated respiratory burst in U937 cells differen-
tiated along an M1 pathway using IFN-g. TSP1 stimulates the
cytotoxic activity of differentiated human U937 cells and murine
ANA-1 cells against several human breast carcinoma and
melanoma cell lines. This contrasts with the reported activity of
U937 cells to support tumor growth in an M2 manner when
coinjected with prostate carcinoma cells (48). We found no effect
of TSP1 on M2 differentiation of these cells in vitro . Therefore,
U937 monocytes have the capacity to differentiate along both
pathways, but TSP1 selectively enhances the cytotoxic effector
function of M1 macrophages.
The NH2-terminal domains of TSP1 and TSP2 are sufficient for
this priming activity but not for PAI-1 induction. The NH2-terminal
domain of TSP1 mediates interactions with several integrin and
nonintegrin receptors (40). Differentiated U937 cells express a4h1
(42) and a6h1 integrins, and inhibition of a6h1 using a TSP1
peptide or a function-blocking a6h1 antibody provides evidence
that this integrin mediates intracellular signaling pathways leading
to increased O2
 production.
Interactions between integrins and their ligands can trigger
transient elevation in intracellular free Ca2+ (43, 44), and Ca2+ is a
well-known intracellular second messenger for signaling the
generation of O2
 in human monocytes (45). We found that
addition of TSP1 to differentiated U937 cells caused a significant
increase in intracellular free Ca2+ and that chelation of extracellular
Ca2+ inhibits the stimulatory effect of TSP1 on mobilization of
intracellular Ca2+ and PMA-mediated O2
 generation in differenti-
ated U937 cells. Taken together, these data suggest that a Ca2+-
dependent mechanism is involved in TSP1 modulation of the
Figure 6. Ca2+ is an intracellular second messenger for activation of the
oxidative burst in TSP1-stimulated U937 monocytic cells. A, analysis of
intracellular free Ca2+ was performed in differentiated U937 cells. U937 cells
(4  105 per condition) were loaded with Fluo-4 for 30 min and then treated with
soluble TSP1 (20 Ag/mL) as described in Materials and Methods. The cells
were then placed in a fluorometer and measurements were acquired for 40 min.
Results are presented as fold induction in TSP1-treated (+) relative to untreated
cells (). Columns, mean of four different experiments; bars, SD. B, analysis
of O2
 release from differentiated U937 cells (5  105 per condition) stimulated
with PMA (100 ng/mL) and soluble TSP1 (20 Ag/mL) in the presence or absence
of EGTA (1 mmol/L) for up to 45 min. The levels of O2
 were determined by
luminescence as described in Fig. 5. The results are presented as a
percentage of control RLU determined in the presence of TSP1 alone and are
representative of two different experiments.
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macrophage respiratory burst. However, we cannot exclude the
possibility that additional receptors recognized by the N-domains
of TSP1 might contribute to O2
 production by macrophages. It is
interesting that the NH2-terminal region of TSP2 shares this activity
to stimulate O2
 production by macrophages. Loss of TSP2 has also
been noted with progression in some cancers, and overexpression
of TSP2 limits tumor growth in murine models (19). Our data
suggest that this may involve both suppression of angiogenesis and
enhancement of innate antitumor immunity.
Soluble TSP1 at 5 Ag/mL was sufficient to increase U937-
mediated cytotoxicity in all tumor cell targets tested. TSP1 was
also reported to directly induce death of MDA-MB-231 and MCF-7
cells when used at 10 Ag/mL for 24 h (49). Our results using a
cytotoxicity assay based on LDH release showed minimal cytotoxic
activity of soluble TSP1 against MDA-MB-231 cells even after 72 h of
incubation. Our data indicate that TSP1 stimulates macrophage-
mediated tumor cell death due to accumulation of ROS.
Physiologic doses of O2
 generated using xanthine/xanthine oxidase
were sufficient to inhibit MDA-MB-231 breast carcinoma cell
viability.
In conclusion, the data presented here show that stimulation of
M1-differentiated human monocytic cells with TSP1 enhances
tumor cell killing in vitro via production of reactive oxygen
intermediates. In vivo , TSP1 promotes M1 macrophage recruitment
into tumors while decreasing tumor growth. Clearly, TSP1 can also
inhibit tumor growth via its antiangiogenic activity, but our results
suggest that TSP1 plays an additional role in tumor immunity by
increasing M1 macrophage recruitment and cytotoxicity. Avoiding
this innate immune surveillance could provide a second selective
pressure to reduce TSP1 expression during tumor progression.
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Elevated production of proinflammatory cytokines and 
chemokines by TSP1-activated human monocytic cells.   
 
 
TSP1 is secreted at sites of injury and inflammation by monocytes 
(1), and differentially regulates the release of IL-6 and IL-10 by U937 
human monocytic cells (2).  However, the underlying mechanism for 
regulation of cytokine expression has not been delineated.  To determine 
the transcriptional events associated with TSP1 regulation of cytokine and 
chemokine expression we performed real-time quantitative reverse 
transcription-PCR analysis of IFNγ-differentiated U937 cells treated for 12 
h with soluble TSP1.  Soluble TSP1 treatment resulted in a significant 
increase or decrease in RNA levels of 31 key genes involved in the 
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Table I.  Genes differentially expressed in TSP1-activated human 
monocytic cellsa. 





Hs.529053 NM_000064 Complement component 3 C3 7.70 
Hs.72918 NM_002981 Chemokine (C-C motif) ligand 1 (I-309) CCL1 4.23 
Hs.414629 NM_005408 Chemokine (C-C motif) ligand 13 (MCP-4) CCL13 7.56 
Hs.143961 NM_002988 Chemokine (C-C motif) ligand 18 (pulmonary and 
activation-regulated) (DC-CK1) CCL18 
2.05 
Hs.303649 NM_002982 Chemokine (C-C motif) ligand 2 (MCP-1) CCL2 3.51 
Hs.75498 NM_004591 Chemokine (C-C motif) ligand 20 (MIP-3α) CCL20 15.33 
Hs.310511 NM_005624 Chemokine (C-C motif) ligand 25 (TECK) CCL25 -3.18 
Hs.514107 NM_002983 Chemokine (C-C motif) ligand 3 (MIP-1α) CCL3 13201.95 
Hs.75703 NM_002984 Chemokine (C-C motif) ligand 4 (MIP-1β) CCL4 20561.73 
Hs.251526 NM_006273 Chemokine (C-C motif) ligand 7 (MCP-3) CCL7 3.27 
Hs.652137 NM_005623 Chemokine (C-C motif) ligand 8 (MCP-2) CCL8 63.52 
Hs.644637 NM_000648 Chemokine (C-C motif) receptor 2 CCR2 -9.04 
Hs.113222 NM_005201 Chemokine (C-C motif) receptor 8 CCR8 -3.22 
Hs.225946 NM_006641 Chemokine (C-C motif) receptor 9 CCR9 -2.05 
Hs.789 NM_001511 Chemokine (C-X-C motif) ligand 1 (melanoma 
growth stimulating activity, alpha) (Gro-α) CXCL1 3.75 
Hs.632586 NM_001565 Chemokine (C-X-C motif) ligand 10 (IP-10) CXCL10 14.35 
Hs.632592 NM_005409 Chemokine (C-X-C motif) ligand 11 (I-TAC) CXCL11 6.00 
Hs.100431 NM_006419 Chemokine (C-X-C motif) ligand 13 (B-cell 
chemoattractant) (BCA-1) CXCL13 
2.85 
Hs.590921 NM_002089 Chemokine (C-X-C motif) ligand 2 (Gro-β) CXCL2 6.15 
Hs.89690 NM_002090 Chemokine (C-X-C motif) ligand 3 (Gro-γ) CXCL3 75.97 
Hs.89714 NM_002994 Chemokine (C-X-C motif) ligand 5 (ENA-78) CXCL5 3.61 
Hs.164021 NM_002993 Chemokine (C-X-C motif) ligand 6 (granulocyte 
chemotactic protein 2) (GCP-2) CXCL6 3.45 
Hs.211575 NM_000605 Interferon, alpha 2 IFNA2 6.15 
Hs.193717 NM_000572 Interleukin 10 IL-10 75.97 
Hs.126256 NM_000576 Interleukin 1, beta IL-1B 3.55 
Hs.166371 NM_173205 Interleukin 1 family, member 7 (zeta) IL-1F7 -2.07 
Hs.624 NM_000584 Interleukin 8 IL-8 8.02 
Hs.960 NM_000590 Interleukin 9 IL-9 3.28 
Hs.406228 NM_002186 Interleukin 9 receptor IL-9R -2.12 
Hs.376208 NM_002341 Lymphotoxin beta (TNF superfamily, member 3) LTB -2.06 
Hs.313 NM_000582 Secreted phosphoprotein 1 (osteopontin, bone 
sialoprotein I, early T-lymphocyte activation 1) SPP1 
4.04 
a The table shows a selection of key genes involved in the inflammatory 
response. In each row, genes show their fold difference between IFNγ-differentiated 
U937 cells untreated or treated with soluble TSP1 (20 μg/ml) for 12 h. 
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To substantiate the response of IFNγ-differentiated U937 cells to 
soluble TSP1 treatment, we further evaluated the protein level of some of 
these target genes by performing Multiplexed ELISA to detect secretion of 
CCL5 (RANTES), IL-6, IL-8, IL-10, CXCL10 (IP-10), CCL1 (I-309), and 
CCL8 (MCP-2) into cell culture medium by differentiated U937 cells upon 
TSP1 treatment.  Consistent with results at the transcriptional level, these 
secreted proteins were also elevated in supernatants collected from 
differentiated U937 cells after TSP1 treatment (Fig. 1).  Incubation of 
differentiated U937 cells with TSP1 resulted in a time-dependent increase 
in RANTES expression, with a maximal 4.8-fold induction at 3 h (Fig. 1, 
p<0.05).  Incubation of differentiated U937 cells with TSP1 resulted in an 
acute time-dependent increase in IL-6, IL-8, and MCP-2 expression, with 
a maximal 89.5-, 8.4-, and 39.4-fold induction at 8, and 12 h, respectively 
(Fig. 1, p≤0.001).  As shown in Fig. 1, TSP1 treatment also led to a (1.6-




















































































































































Figure 1.  Elevated production of proinflammatory 
cytokines and chemokines by TSP1-activated 
human monocytic cells.  
IFNγ-differentiated U937 cells (1 x 106/0.5 ml RPMI 1640 with 0.5% 
FBS) were incubated for 3, 6, 8, 12, and 24 h in the absence or the presence 
of soluble TSP1 (20 μg/ml).  CCL5 (RANTES), IL-6, IL-8, IL-10, CXCL10 (IP-
10), CCL1 (I-309), and CCL8 (MCP-2) levels in the culture supernatant were 
determined using a multiplexed ELISA array (Quansys Biosciences), as 
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Because the N-terminal module of TSP1 increases FMLP-
mediated O2- generation and chemotaxis by human neutrophils (3, 4), 
and PMA-mediated O2- generation by IFNγ-differentiated U937 human 
monocytic cells (5), we examined the role of the N-terminal module of 
TSP1 in mediating cytokine and chemokine expression.  Using an anti-
TSP monoclonal antibody against the N-terminal module of TSP1, 
designated A2.5 (6), we found that incubation of IFNγ-differentiated U937 
cells with soluble TSP1 (20 μg/ml) in the presence of the monoclonal 
antibody A2.5 (10 μg/ml) did not alter RANTES and I-309 secretion (Fig. 
2A).  Because different modules of TSP1 often mediate opposite effects, 
we examined the role of the C-terminal domain of TSP1 in mediating 
cytokine and chemokine expression.  We used an anti-TSP monoclonal 
antibody against the C-terminal module of TSP1, designated C6.7 (6, 7), 
and we found that incubation of IFNγ-differentiated U937 cells with 
soluble TSP1 (20 μg/ml) in the presence of the monoclonal antibody C6.7 
(10 μg/ml) resulted in a time-dependent increase in RANTES expression 
(Fig. 2A left, p<0.001), suggesting that the C-terminal domain of TSP1 
can mediate inhibition of RANTES expression at the late time points of 12 
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Alternatively, the antibody may increase and prolong a stimulation 
mediated by a different domain of TSP1 by cross-linking TSP1. 
 
In addition, we found that 24 h incubation of IFNγ-differentiated 
U937 cells with soluble TSP1 (20 μg/ml) in the presence of the 
monoclonal antibody A2.5 (10 μg/ml) resulted in a significant increase in 
IL-6 expression (Fig. 2B, p<0.001).  Moreover, incubation of IFNγ-
differentiated U937 cells with soluble TSP1 in the presence of the 
monoclonal antibody A2.5 resulted in an increase in IL-8, IL-10, and IP-10 
expression (Data not shown).  Our data suggest that the N-terminal 
domain of TSP1 can mediate inhibition of IL-6, IL-8, IL-10, and IP-10 
expression at the late time points of 12 and 24 h.  Alternatively, these 
increased responses may also result from cross-linking of TSP1 by the 
antibody. 
 
On the contrary, we found that 24 h incubation of IFNγ-
differentiated U937 cells with soluble TSP1 (20 μg/ml) in the presence of 
the monoclonal antibody A2.5 (10 μg/ml) resulted in a significant 
decrease in MCP-2 expression (Fig. 2C, p<0.05), indicating that the N-
terminal domain of TSP1 can mediate stimulation of MCP-2 expression, 
which is blocked by this antibody.   
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All this complexity is due to the conformational flexibility of TSP1, 
and the distinct expression profiles and activity status of the TSP1 
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Figure 2.  Role of the N-terminal domain of TSP1 in mediating 
cytokine and chemokine expression 
A-C, IFNγ-differentiated U937 cells (1 x 106/0.5 ml RPMI 1640 with 
0.5% FBS) were incubated for 3, 12, and 24 h in the absence or the 
presence of soluble TSP1 (20 μg/ml), and anti-TSP monoclonal antibodies 
A2.5 and C6.7 (10 μg/ml).  CCL5 (RANTES), CCL1 (I-309), IL-6, IL-8, IL-10, 
CXCL10 (IP-10), and CCL8 (MCP-2) levels in the culture supernatant were 
determined using a multiplexed ELISA array (Quansys Biosciences), as 
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Role of TGF-β1 in TSP1-mediated cytokine and chemokine 
expression by human monocytic cells. 
 
 
PAI-1 is a TGF-β-inducible gene (8), and bioactive TGF-β present 
in platelet TSP1 (9) at least partially, mediates the stimulation of PAI-1 
production by U937 cells (5).  To determine whether TGF-β contributed to 
cytokine and chemokine responses in U937 cells, we first employed 
recombinant human TGF-β1, and we found that 12 h incubation of IFNγ-
differentiated U937 cells with different doses of TGF-β1 resulted in a 
significant decrease in IL-8 and RANTES expression (Fig. 3A-B).  In 
addition, we found that 12 h incubation of IFNγ-differentiated U937 cells 
with 1 ng/ml of TGF-β1 resulted in a significant increase in MCP-2 



















































































Figure 3.  Role of TGF-β1 in cytokine and chemokine 
expression by human monocytic cells 
A-C, IFNγ-differentiated U937 cells (1 x 106/0.5 ml RPMI 
1640 with 0.5% FBS) were incubated for 12 h in the absence or the 
presence of different doses of recombinant human TGF-β1.  IL-8, 
CCL5 (RANTES), and CCL8 (MCP-2) levels in the culture 
supernatant were determined using a multiplexed ELISA array 
(Quansys Biosciences), as described in Materials and Methods. 
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To determine whether TSP1-mediated activation of latent TGF-β 
(10) plays a role in MCP-2 release from differentiated U937 cells, we first 
examined the ability of recombinant 3TSR, the type 1 repeat domain of 
TSP1 responsible for the TSP1-mediated activation of latent TGF-β (11), 
to induce MCP-2 expression.  The total amount of MCP-2 released from 
differentiated U937 cells did not change after treatment with 3 μg/ml of 
soluble recombinant 3TSR (Fig. 4).  Therefore, activation of latent TGF-β 
probably does not account for the effect of TSP1 on total MCP-2 
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Figure 4.  Role of TSP1-mediated activation of latent  
TGF-β1 in MCP-2 expression by human monocytic cells 
IFNγ-differentiated U937 cells (1 x 106/0.5 ml RPMI 1640 with 0.5% 
FBS) were incubated for 12 h in the absence or the presence of soluble 
TSP1 (20 μg/ml), or soluble recombinant type 1 repeats of TSP1 (3TSR) (3 
μg/ml).  CCL8 (MCP-2) levels in the culture supernatant were determined 
using a multiplexed ELISA array (Quansys Biosciences), as described in 
Materials and Methods. 
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To test the hypothesis that bioactive TGF-β present in platelet 
TSP1 (9) regulates the cytokine and chemokine response in U937 cells, 
TSP1 stimulation of IL-8, RANTES, and MCP-2 production was then 
examined in the presence of recombinant human TSP1, which should 
lack TGF-β contamination, and a neutralizing TGF-β1 antibody (Fig. 5).  
Incubation of differentiated U937 cells with recombinant human TSP1 (20 
μg/ml) resulted in a significant increase in IL-8 and RANTES expression, 
compared with platelet TSP1 (Fig. 5A, B, respectively, p<0.05).  
Furthermore, recombinant human TSP1 at the same concentration in the 
presence of 1 ng/ml of recombinant TGFβ1, showed less stimulatory 
activity than recombinant TSP1 alone (Fig. 5A).  These results are 
consistent with our early observation that IL-8 and RANTES expression is 
inhibited by TGF-β1 in human monocytic cells (Fig. 3).  In addition, TSP1 
stimulation of MCP-2 production was examined in the presence of a 
neutralizing TGF-β1 antibody.  At 5 μg/ml the neutralizing antibody 
partially inhibited TSP1-stimulated MCP-2 production (Fig. 5C, p<0.05).  
This result is consistent with our early observation that MCP-2 expression 
is enhanced by TGF-β1 in human monocytic cells (Fig. 3).  Therefore, 
bioactive TGF-β present in platelet TSP1 at least partially mediates the 
stimulation of MCP-2 production by TSP1, but TSP1 lacking TGF-β is 
also active. 
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Figure 5.  Effects of TGF-β1 on TSP1-mediated cytokine and 
chemokine expression in differentiated U937 human monocytic 
cells 
A-B, differentiated U937 cells (1 x 106/0.5 ml RPMI 1640 with 0.5% 
FBS) were incubated in the absence or the presence of soluble TSP1 (20 
μg/ml), soluble recombinant human TSP1 (20 μg/ml), and recombinant 
human TGF-β1 (1 ng/ml).  After 12 h incubation the supernatants were 
harvested, and total IL-8, and RANTES were determined using a multiplexed 
ELISA array (Quansys Biosciences), as described in Materials and Methods.  
Data represent the average and the standard deviation of two independent 
experiments.  C, soluble TSP1 (20 μg/ml) was pre-incubated with neutralizing 
TGF-β1 antibody (clone 9016) for 45-60 min before addition to the 
differentiated U937 cells.  Culture supernatants collected after 12 h were used 
to measure total MCP-2.   
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Identification of NF-κB as a downstream effector of TSP1-
mediated cytokine and chemokine expression. 
 
 
It is well established that NF-κB plays a role in the regulation of a 
variety of proinflammatory cytokines and chemokines.  To address 
whether the increased production of proinflammatory cytokines and 
chemokines was caused by activation of NF-κB in TSP1-stimulated U937 
human monocytic cells, we transfected IFNγ-differentiated U937 cells with 
a luciferase reporter driven by five copies of the NF-κB binding sites.  2 
days after transfection, the cells were treated for 90 min with various 
stimuli.  Incubation with PMA (100 ng/ml) or soluble TSP1 (20 μg/ml) 
caused a 6-fold increase in the NF-κB-mediated gene activation.  In 
addition, incubation of differentiated U937 cells with soluble TSP1 
increased PMA-mediated NF-κB activation (Fig. 6).  Therefore, the 
increased production of some of the proinflammatory cytokines and 
chemokines is likely due to enhanced NF-κB signaling pathway after 
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Figure 6.  Increased NF-κB activity in TSP1-stimulated 
human monocytic cells 
Differentiated U937 cells were co-transfected with pNF-κB-luc 
or pCIS-CK-luc (negative control), and phRL-Renilla.  The cells were 
treated with PMA (100 ng/ml), soluble TSP1 (20 μg/ml), LPS (100 
ng/ml), or fMLP (10-5M) for 90 min.  Cell lysates were collected and 
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Varios estudios indican que la TSP1 juega un papel importante en 
el reclutamiento de monocitos y de macrófagos en tejidos que han sufrido 
algún tipo de daño y en focos inflamatorios (1, 2).  En este trabajo 
aportamos evidencias de que la sobreexpresión de TSP1 en tumores 
aumenta el reclutamiento de macrófagos in vivo.  Las células tumorales 
producen una amplia variedad de factores quimiotácticos para los 
macrófagos.  In vivo, la proteína-1 quimiotáctica para monocitos (MCP-1) 
estimula el reclutamiento de macrófagos al tumor (3).  La disminución en 
la expresión de esta quimioquina también limita la infiltración de 
macrófagos en excisional wounds en ratones nulos para la TSP1 (1).  No 
obstante, la incubación con TSP1 soluble de la línea celular monocítica 
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In vitro, el inhibidor-1 del activador de plasminógeno (PAI-1) es 
necesario para la migración celular (4) y recientes estudios proponen es 
un factor crítico para la migración de los macrófagos tanto in vitro como 
in vivo (5).  En células de cáncer de páncreas, la TSP1 es capaz de 
estimular la secreción del PAI-1 (6), así como en la línea celular MDA-
MB-435 que sobreexpresa TSP1 (7).  En nuestras manos, monocitos 
humanos diferenciados y macrófagos de ratón, responden al tratamiento 
con TSP1 con un aumento significativo de la secreción del PAI-1.  In vivo, 
los TAMs procedentes de tumores que sobreexpresan TSP1 producen 
cantidades elevadas del PAI-1.  Este cambio dramático en la expresión 
del PAI-1 en respuesta a la TSP1 está mediado, al menos en parte, por 
el TGF-β.  Las repeticiones de tipo 1 de la TSP1 tienen la capacidad de 
interaccionar con el TGF-β latente y promover su activación.  No 
obstante, este dominio de la TSP1 no presenta actividad ninguna en 
relación a la inducción del PAI-1.  Por lo tanto, la TSP1 probablemente 
induce la secreción del PAI-1 a través del TGF-β activo que lleva unido, y 
no a través de la activación del TGF-β latente producido por las células 
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Aunque no descartamos la posibilidad de que otras citoquinas 
puedan estar implicadas, la inducción autocrina del PAI-1 por parte de la 
TSP1 procedente de la célula tumoral, así como la inducción paracrina 
del PAI-1 en los TAMs, puede ser responsable del aumento en el 
infiltrado de macrófagos en el tumor. 
 
El impacto que el aumento en el reclutamiento de macrófagos 
pueda tener en el crecimiento o disminución del tumor está en función del 
grado de diferenciación de estos macrófagos.  El ambiente del tumor 
tiende a educar a los TAMs hacia un fenotipo promotor del tumor (8) y 
así, previene la migración de más macrófagos y se asegura la producción 
constante de factores de crecimiento y angiogénicos.  En este estudio 
hemos descubierto que la expresión de TSP1 en el tumor, no sólo induce 
la migración de macrófagos estimulando la señalización vía PAI-1 en los 
TAMs, si no que favorece la migración selectiva de macrófagos de 
fenotipo M1.  Esto podría favorecer el proceso de selección natural y, 
junto con su actividad anti-angiogénica, explicaría la represión en la 
expresión de la TSP1 que a menudo tiene lugar durante la progresión 
tumoral, así como la capacidad de esta proteína de inhibir el crecimiento 
tumoral cuando se reexpresa. 
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En general, los macrófagos con fenotipo M1 son productores 
eficaces de intermediarios de oxígeno y de nitrógeno, que median los 
procesos de resistencia contra el tumor (9).  En este estudio, la detección 
de la enzima óxido nítrico sintetasa inducible (iNOS) pone de manifiesto 
que la expresión de la TSP1 en el tumor induce la polarización de los 
TAMs hacia un fenotipo M1. 
 
Estudios previos han demostrado que la TSP1 es capaz de 
potenciar el respiratory burst inducido por citoquinas y por el factor 
quimiotáctico fMLP en neutrófilos humanos (10, 11).  En el presente 
trabajo de investigación demostramos que la TSP1 potencia el 
respiratory burst inducido por PMA en la línea celular U937 diferenciada 
hacia un fenotipo M1 usando IFN-γ.  La TSP1 estimula la actividad 
citotóxica de las células U937 diferenciadas y de la línea celular de 
macrófagos de ratón ANA-1, para con distintas líneas celulares de cáncer 
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Por el contrario, las células U937 adquieren un fenotipo M2 
promotor del crecimiento tumoral cuando se inyectan junto con células de 
cáncer de próstata (12).  In vitro, no observamos efecto ninguno de la 
TSP1 en la diferenciación de tipo M2 de estas células.  Por lo tanto, 
aunque los monocitos U937 parecen tener la capacidad de diferenciarse 
en ambos sentidos, la TSP1 estimula específicamente la función efectora 
citotóxica de los macrófagos M1. 
 
Los dominios N-terminal de las TSP1 y 2 son suficientes para 
estimular el respiratory burst pero no para inducir la secreción del PAI-1.  
El dominio N-terminal de la TSP1 media la interacción con distintos 
receptores de tipo integrina y no-integrina (13).  Las células U937 
diferenciadas expresan las integrinas de tipo α4β1 (14) y α6β1.  La 
inhibición de la integrina α6β1, usando anticuerpos que bloquean su 
función o péptidos de la TSP1, pone de manifiesto que a través de esta 
integrina se produce la activación de los mecanismos de señalización 
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Las interacciones entre integrinas y sus ligandos pueden promover 
una elevación transitoria en los niveles intracelulares de Ca2+ libre (15, 
16).  Está ampliamente aceptado el papel del Ca2+ como segundo 
mensajero intracelular en la señalización que conduce a la generación de 
O2- en monocitos humanos (17).  En este trabajo demostramos por un 
lado, que la incubación con TSP1 de células U937 diferenciadas hacia un 
fenotipo M1 se traduce en un aumento significativo en los niveles 
intracelulares de Ca2+ libre y por otro, que quelando el Ca2+ extracelular 
inhibimos el efecto estimulador de la TSP1 en la movilización del Ca2+ 
intracelular y la producción de O2- en células U937 diferenciadas y 




























Modelo I.  La Trombospondina-1 induce la producción de 
O2- extracelular 
 
En resumen, estos datos sugieren que un mecanismo dependiente 
de Ca2+ está implicado en la modulación del respiratory burst en 
macrófagos por la TSP1.  No obstante, no podemos excluir la posibilidad 
de que otros receptores adicionales reconocidos por el dominio N-
terminal de la TSP1 estén involucrados en la regulación de la producción 
de O2- en los macrófagos. 
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Resulta interesante que la región N-terminal de la TSP2 comparta 
esta actividad estimuladora de la producción de O2- en macrófagos.  La 
pérdida de la TSP2 también está asociada a la progresión de algunos 
cánceres y su sobreexpresión limita el crecimiento tumoral en modelos 
experimentales en ratón (18).  Los datos presentados en este estudio, 
sugieren que esta pérdida puede estar relacionada tanto con la supresión 
de la angiogénesis como con la potenciación de la respuesta inmune 
innata anti-tumoral. 
 
La TSP1 en solución a una concentración de 5 μg/ml es suficiente 
para aumentantar la citotoxicidad de las células U937 contra todas las 
líneas celulares tumorales empleadas.  La TSP1 puede inducir 
directamente la muerte celular en las líneas celulares de cáncer de 
mama MDA-MB-231 y MCF-7 cuando se usa en concentraciones de 10 
μg/ml durante 24 h (19).  Los resultados obtenidos de los ensayos de 
citotoxicidad basados en la liberación de la lactato deshidrogenada (LDH) 
muestran una actividad citotóxica mínima de la TSP1 en solución para 
con la línea celular MDA-MB-231, incluso después de 72 h de 
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Los datos presentados en este trabajo indican que el mecanismo 
por el que la TSP1 estimula la muerte de la célula tumoral mediada por 
macrófagos está relacionado con la acumulación de ROS.  Así pues, la 
incubación de la línea celular de cáncer de mama MDA-MB-231 con 
dosis fisiológicas de O2-, fruto de la reacción enzimática de la 
xantina/xantina oxidasa, resulta suficiente para inhibir la viabilidad de 
estas células. 
 
Los macrófagos activados y diferenciados de forma clásica como 
M1 no son sólo productores eficaces de intermediarios de oxígeno y de 
nitrógeno, si no que también lo son de citoquinas inflamatorias (9).  
Estudios previos han demostrado que la TSP1 es capaz de regular la 
producción de las IL-6 y -10 procedentes de células U937 estimuladas 
con PMA y lipopolisacárido (LPS) (20).  En este trabajo de investigación 
demostramos que la TSP1 en solución aumenta la producción de 
citoquinas y quimioquinas proinflamatorias en las células U937 
diferenciadas a macrófagos M1 usando IFN-γ, e identificamos al factor de 





REGULATION OF INNATE IMMUNE RESPONSES 
 
 
La TSP1 estimula la secreción de la IL-8 y de RANTES, 
quimioquinas relacionadas con el reclutamiento de neutrófilos y de 
leucocitos respectivamente, procedente de las células U937 
diferenciadas con IFN-γ.  Usando el TGF-β1 y la TSP1 recombiantes 
demostramos que el TGF-β1 bioactivo presente en la TSP1 procedente 
de plaquetas (21) regula negativamente la expresión de estas citoquinas.   
 
Los datos presentados en este trabajo indican que la TSP1 induce 
significativamente la producción de la MCP-2 por parte de macrófagos 
humanos diferenciados.  Este cambio significativo en la expresión de la 
MCP-2 en respuesta a la TSP1 está mediado, al menos en parte, por el 
TGF-β.  Las repeticiones de tipo 1 de la TSP1 llevan a cabo la activación 
del TGF-β latente, pero este dominio no induce la expresión de la MCP-
2.  Por lo tanto, la TSP1 probablemente induce la secreción de la MCP-2 
a través del TGF-β activo unido a la TSP1 y no de la activación del TGF-
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Usando anticuerpos monoclonales dirigidos contra los dominios N- 
y C-terminal de la TSP1 deducimos que el dominio N-terminal de la TSP1 
puede estar mediando la inhibición de la expresión de las citoquinas IL-6, 
IL-8, IL-10 y de la quimioquina IP-10 y que el dominio C-terminal de la 
TSP1 puede estar mediando la inhibición de la expresión de RANTES.  
Una interpretación alternativa es que el anticuerpo aumenta la 
estimulación mediada por un dominio diferente de la TSP1 a través del 
cross-linking de la misma.  La inhibición en la expresión de la MCP-2 
usando un anticuerpo monoclonal dirigido al dominio N-terminal de TSP1 
proporciona evidencias de que este dominio está mediando la 
señalización intracelular que conduce al aumento en la expresión de la 
MCP-2.   
 
En conclusión, los datos presentados en este estudio demuestran 
que la estimulación con TSP1 de monocitos humanos diferenciados a 
macrófagos de tipo M1, aumenta la capacidad de éstos de reconocer y 
desencadenar la muerte de la célula tumoral in vitro a través de la 
producción de intermediarios reactivos de oxígeno y de la expresión de 
citoquinas y quimioquinas.  In vivo, la TSP1 promueve el reclutamiento 
de macrófagos de tipo M1 al tumor, al tiempo que disminuye el 
crecimiento tumoral.   
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Por supuesto, la TSP1 inhibe el crecimiento tumoral a través de su 
actividad anti-angiogénica, pero los resultados presentados en este 
trabajo sugieren que la TSP1 puede estar jugando un papel adicional en 
la inmunidad tumoral al aumentar el reclutamiento y la citotoxicidad de 
los macrófagos de tipo M1.  De este modo, la posibilidad de evadir la 
vigilancia inmune innata podría justificar el proceso de selección natural 
que tiende a reducir la expresión de la TSP1 y/o de la TSP2 durante la 
















Modelo II.  Papel de la Trombospondina-1 en la inmunidad 
tumoral 






Several studies have suggested that TSP1 plays an important role 
in the recruitment of monocytes and macrophages to sites of tissue injury 
or inflammation (1, 2).  Here we provide evidence that over-expression of 
TSP1 in tumors increases macrophage recruitment in vivo.  Tumor cells 
produce a range of chemotactic factors for macrophages.  MCP-1 
stimulates recruitment of macrophages into tumors in vivo (3), and 
decreased expression of this chemokine was reported to limit infiltration 
of macrophages into an excisional wound in TSP1 null mice (1).  
However, soluble TSP1 did not increase MCP-1 release from 
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PAI-1 is also required for cell migration in vitro (4), and evidence is 
emerging for a critical role of PAI-1 in macrophage migration in vitro and 
in vivo (5).  TSP1 up-regulates PAI-1 in pancreatic cancer cells (6), and 
PAI-1 expression is up-regulated in TSP1-expressing MDA-MB-435 cells 
(7).  We found that TSP1 acutely increased PAI-1 production by 
differentiated human and mouse macrophages, and strong TAM 
expression of PAI-1 was observed in TSP1 over-expressing tumors in 
vivo.  This acute change in PAI-1 expression in response to TSP1 is at 
least partially TGF-β-mediated.  Activation of latent TGF-β is mediated by 
the type 1 repeats of TSP1, but we found no induction of PAI-1 by this 
domain.  Therefore, TSP1 probably induces PAI-1 via bound active TGF-
β rather than activation of latent TGF-β produced by U937 cells.  
Although additional cytokines may be involved, autocrine induction of 
PAI-1 via tumor-cell produced TSP1 as well as paracrine induction of PAI-
1 expression in TAMs could increase macrophage recruitment into the 
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Whether increased macrophage recruitment inhibits or enhances 
tumor growth depends on their differentiation state.  The tumor 
environment can educate TAMs toward a tumor-promoting phenotype 
(M2) (8), which may prevent further macrophage migration within the 
tumor and ensure constant production of growth and angiogenic factors.  
In addition to contributing to macrophage infiltration by stimulating PAI-1 
signaling in TAMs, we found that TSP1 expression in the tumor 
selectively increases M1 macrophage infiltration.  This may provide a 
selective pressure distinct from its anti-angiogenic activity to account for 
the frequently observed down-regulation of TSP1 during tumor 
progression and its ability to inhibit tumor growth when re-expressed.   
 
In general, M1 macrophages are efficient producers of reactive 
oxygen and nitrogen intermediates that mediate resistance against 
tumors (9).  Here we provide evidence that tumor expression of TSP1 
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TSP1 was previously shown to enhance cytokine- and 
chemoattractant fMLP-induced respiratory burst in human neutrophils (10, 
11).  We now demonstrate that TSP1 enhances PMA-mediated 
respiratory burst in U937 cells differentiated along an M1 pathway using 
IFN-γ.  TSP1 stimulates the cytotoxic activity of differentiated human 
U937 cells and murine ANA-1 cells against several human breast 
carcinoma and melanoma cell lines.  This contrasts with the reported 
activity of U937 cells to support tumor growth in an M2 manner when co-
injected with prostate carcinoma cells (12).  We found no effect of TSP1 
on M2 differentiation of these cells in vitro.  Therefore, U937 monocytes 
have the capacity to differentiate along both pathways, but TSP1 
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The N-terminal domains of TSP1 and TSP2 are sufficient for this 
priming activity but not for PAI-1 induction.  The N-terminal domain of 
TSP1 mediates interactions with several integrin and non-integrin 
receptors (13).  Differentiated U937 cells express α4β1 (14) and α6β1 
integrins, and inhibition of α6β1 using a TSP1 peptide or a function-
blocking α6β1 antibody provide evidence that this integrin mediates 
intracellular signaling pathways leading to increased O2-production.   
 
Interactions between integrins and their ligands can trigger a 
transient elevation in intracellular free Ca2+ (15), (16), and Ca2+ is a well 
known intracellular second messenger for signaling the generation of O2- 
in human monocytes (17).  We found that addition of TSP1 to 
differentiated U937 cells caused a significant increase in intracellular free 
Ca2+, and that chelation of extracellular Ca2+ inhibits the stimulatory effect 
of TSP1 on mobilization of intracellular Ca2+ and PMA-mediated O2- 























Model I.  TSP1 increases extracellular release of O2-
 
Taken together, these data suggest that a Ca2+-dependent 
mechanism is involved in TSP1 modulation of the macrophage respiratory 
burst.  However, we can not exclude the possibility that additional 
receptors recognized by the N-domains of TSP1 might contribute to O2- 
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It is interesting that the N-terminal region of TSP2 shares this 
activity to stimulate O2- production by macrophages.  Loss of TSP2 has 
also been noted with progression in some cancers, and over-expression 
of TSP2 limits tumor growth in murine models (18).  Our data suggest this 
may involve both suppression of angiogenesis and enhancement of 
innate anti-tumor immunity. 
 
Soluble TSP1 at 5 μg/ml was sufficient to increase U937-mediated 
cytotoxicity in all tumor cell targets tested.  TSP1 was also reported to 
directly induce death of MDA-MB-231 and MCF-7 cells when used at 10 
μg/ml for 24 h (19).  Our results using a cytotoxicity assay based on LDH 
release showed minimal cytotoxic activity of soluble TSP1 against MDA-
MB-231 cells, even after 72 h of incubation.  Our data indicate that TSP1 
stimulates macrophage-mediated tumor cell death due to accumulation of 
ROS.  Physiologic doses of O2- generated using xanthine/xanthine 
oxidase were sufficient to inhibit MDA-MB-231 breast carcinoma cell 
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Classically polarized activated M1 macrophages are not only 
proficient producers of reactive oxygen and nitrogen intermediates but 
also efficient producers of inflammatory cytokines (9).  TSP1 was 
previously shown to regulate the release of IL-6 and IL-10 by U937 cells 
stimulated with PMA and lipopolysaccharide (LPS) (20).  We now 
demonstrate that soluble TSP1 enhances the production of 
proinflammatory cytokines and chemokines in U937 cells differentiated 
along an M1 pathway using IFN-γ, and identify NF-κB as a downstream 
effector. 
 
TSP1 stimulated the release of RANTES and IL-8, chemokines 
involved in mixed leukocyte and neutrophil recruitment, respectively, by 
IFN-γ-differentiated human U937 cells.  Our results using recombinant 
TGF-β1 and recombinant TSP1 showed negative regulation of these 
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We found that TSP1 acutely increased MCP-2 production by 
differentiated human macrophages.  This acute change in MCP-2 
expression in response to TSP1 is at least partially TGF-β-mediated.  
Activation of latent TGF-β is mediated by the type 1 repeats of TSP1, but 
we found no induction of MCP-2 by this domain.  Therefore, TSP1 
probably induces MCP-2 via bound active TGF-β rather than activation of 
latent TGF-β produced by U937 cells. 
 
Our results using anti-TSP monoclonal antibodies against the N- 
and C-terminal domains of TSP1 suggest that the N-terminal domain of 
TSP1 can mediate inhibition of IL-6, IL-8, IL-10, and IP-10 expression, 
and the C-terminal domain of TSP1 can mediate inhibition of RANTES 
expression.  Alternatively, the antibody may increase a stimulation 
mediated by a different domain of TSP1 by cross-linking TSP1.  Inhibition 
of MCP-2 expression using an anti-TSP monoclonal antibody against the 
N-terminal domain of TSP1 provides evidence that this domain mediates 
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In conclusion, the data presented here demonstrate that 
stimulation of M1 differentiated human monocytic cells with TSP1 
enhances tumor cell killing in vitro via production of reactive oxygen 
intermediates, and cytokine and chemokine expression.  In vivo, TSP1 
promotes M1 macrophage recruitment into tumors while decreasing 
tumor growth.  Clearly, TSP1 can also inhibit tumor growth via its anti-
angiogenic activity, but our results suggest that TSP1 plays an additional 
role in tumor immunity by increasing M1 macrophage recruitment and 
cytotoxicity.  Avoiding this innate immune surveillance could provide a 
second selective pressure to reduce TSP1 and/or TSP2 expression 
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1.  La sobreexpresión de TSP1 en células de melanoma, aumenta 
el reclutamiento de macrófagos en tumores xenotrasplantados en ratones 
atímicos de tipo nude y beige/nude.  In vitro, la TSP1 induce 
significativamente la expresión por parte de monocitos del inhibidor-1 del 
activador de plasminógeno, lo que sugiere que el reclutamiento de 
macrófagos en respuesta a la TSP1 está mediado, al menos en parte, 
por el inhibidor-1 del activador de plasminógeno.  
 
2.  Los tumores que sobreexpresan TSP1 presentan un porcentaje 
más elevado de macrófagos de fenotipo M1 caracterizados por la 










3.  In vitro, la TSP1 aumenta la actividad citotóxica de las células 
U937 diferenciadas con IFN-γ, induciendo la muerte celular de distintas 
líneas celulares de cáncer de mama y de melanoma, a través de la 
producción de especies reactivas de oxígeno. 
 
4.  La incubación con TSP1 de monocitos diferenciados y 
estimulados con PMA, promueve un aumento significativo en la 
producción de radical superóxido a través de la interacción de su dominio 
NH2-terminal con el receptor de tipo integrina α6β1.  El dominio NH2-
terminal de la TSP2 también estimula la producción de radical superóxido 
en monocitos.  La TSP1 requiere la presencia de calcio extracelular para 
inducir el respiratory burst en macrófagos. 
 
5. In vitro, la TSP1 induce significativamente la expresión de 
RANTES, IL-6, IL-8, IL-10, IP-10, I-309 y de la proteína-2 quimiotáctica 
para monocitos, en células monocíticas U937 diferenciadas a un fenotipo 
M1.  NF-κB es un efector en esta ruta de señalización que conduce a la 
expresión de citoquinas y quimioquinas en respuesta a TSP1.  In vitro, la 








La TSP1 juega un papel relevante en la inmunidad anti-
tumoral al aumentar el reclutamiento y la activación de los 
macrófagos de fenotipo M1 asociados al tumor, lo que justifica el 
proceso de selección natural que favorece la represión en la 


























1. Overexpression of TSP1 in melanoma cells increases 
macrophage recruitment into xenograft tumors grown in nude or 
beige/nude mice. In vitro, TSP1 acutely induces expression of 
plasminogen activator inhibitor-1 by monocytic cells, suggesting that 
TSP1-induced macrophage recruitment is at least partially mediated by 
plasminogen activator inhibitor-1.  
 
2. The percentage of M1-polarized macrophages expressing 
inducible nitric oxide synthase is increased in TSP1-expressing tumors. 
 
3. TSP1 stimulates killing of breast carcinoma and melanoma cells 












4. TSP1 causes a significant increase in PMA-mediated 
superoxide generation from differentiated monocytes by interaction with 
α6β1 integrin through its NH2-terminal region. The NH2-terminal domain 
of TSP2 also stimulates monocyte superoxide production. Extracellular 
calcium is required for the TSP1-induced macrophage respiratory burst. 
 
5. In vitro, TSP1 acutely induces expression of RANTES, IL-6, IL-
8, IL-10, IP-10, I-309, and Monocyte Chemoattractant Protein-2 by M1-
differentiated U937 monocytic cells. NF-κB is a downstream effector of 
TSP1-mediated cytokine and chemokine expression. M2 macrophage 
differentiation or function in vitro is not sensitive to TSP1. 
 
TSP1 play an important role in anti-tumor immunity by 
enhancing recruitment and activation of M1 tumor-associated 
macrophages, which provides an additional selective pressure for 

































B.ADDITIONAL MATERIALS AND METHODS 
 
 
Proteins and peptides.  Human TSP1 was purified from the 
supernatant of thrombin-activated platelets obtained from the NIH Blood 
Bank (1).  Recombinant protein containing the type I repeat domain of 
TSP1 (3TSR) was prepared as previously described and provided by Dr. 
Jack Lawler (Harvard University) (2).  Recombinant human TSP1 was 
obtained from EMP Genetech. 
 
Reagents.  Monoclonal neutralizing antibody (clone 9016) against 
human TGFβ1, recombinant human IFN-γ, and recombinant human TGF 
β1 were from R&D Systems.  Anti-TSP mouse monoclonal antibodies Ab-
6 (clone A2.5) and Ab-3 (clone C6.7) were from Thermo Scientific.  LPS 
from Escherichia coli 0111:B4, PMA and FMLP were obtained from 








Cell culture and differentiation.  The human monocytic line U937 
(3) kindly provided by Dr. Mark Raffeld (NCI, NIH, Bethesda, MD) was 
cultured at 37 ºC, 5% CO2, in RPMI-1640 supplemented with 2 mM 
glutamine, 100 units/ml penicillin, 100 μg/ml streptomycin, and 10% 
endotoxin tested FBS (Biosource).  For differentiation with IFN-γ, 2.0x105 
U937cells/ml in complete growth medium containing 1mM sodium 
pyruvate, 0.1mM MEM with non-essential amino acids (Cellgro), and 40-
100 U/ml recombinant human IFN-γ were incubated for 3 days at 37ºC.. 
 
Real-time quantitative reverse transcription-PCR analysis.  
Total RNA was extracted from U937 cells using Absolutely RNA Miniprep 
Kit (Stratagene), according to the manufacturer’s instructions.  Total RNA 
was quantified using the NanoDrop ND-1000 Spectrophotometer (Nano-
Drop Technologies).  cDNA was synthesized from total RNA using iScript 












Real-time quantitative reverse transcription-PCR analysis was 
performed on a Bio-Rad iCycler Real Time PCR instrument using the RT2 
Profiler PCR Array for human inflammatory cytokines and receptors 
(SuperArray Bioscience Corporation).  Data were normalized against 
human β-2-microglobulin (B2M: NM_004048).  Relative gene expression 
was calculated using the 2– CT method. 
 
Measurement of human cytokines and chemokines.  Human 
cytokines and chemokines levels in differentiated U937 cells supernatants 
were measured with a Multiplexed ELISA array (Quansys Biosciences). 
All samples were run in replicate. 
 
Plasmids.  PathDetect® cis-Luciferase reporter plasmids 
containing five copies of the NF-κB binding sites (p NF-κB-luc), and 
negative control (pCIS-CK-luc), were obtained from Stratagene.  Renilla 











Transient Transfection and Luciferase Assay.  Differentiated 
U937 cells were transfected with 1 μg of total DNA (0.8 μg pNF-κB-luc, 
0.2 μg phRL-Renilla, and 0.8 μg pCIS-CK-luc) in room temperature Cell 
Line Nucleofector Solution V to a final concentration of 1.0x106 U937cells 
per 100 μl reaction using Nucleofector (Amaxa biosystems).  After 
transfection, cells were cultured in complete medium for 48 h.  Cells were 
then seeded into 24-well plates in 200 μl of complete medium and 
stimulated with PMA, LPS, FMLP, and TSP1 for 90 min.  Cells were then 
lysed in passive lysis buffer (Promega), and luciferase activity of protein 
samples was determined by the Dual-Luciferase® Reporter Assay 
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